AmTrust International Underwriters DAC

Solvency and Financial Condition Report

For the year ending 31 December 2024



An AmTrust Financial Company

Glossary of Te	erms	2
Executive Sur	mmary	3
A. Business	s and Performance	11
A.1 Bus	siness Profile	11
A.2 Und	derwriting Performance	15
A.3 Inve	estment Performance	18
A.4 Per	formance of other activities	19
A.5 Any	other information	19
B. System of	of Governance	21
B.1 Ger	neral information on the system of governance	21
	and Proper Requirements	
	k management system including the own risk solvency assessment	
	ernal control system	
	ernal audit function	
	uarial function	
	tsourcing	
	other information	
,	file	
C.1 Und	derwriting risk	11
	rket Risk	
	rdit risk	
	uidity risk	
'	erational risk	
'	ner material risks	
	/ other information	
,	n for solvency purposes	
D.1 Ass		57
	chnical Provisions	
	iabilities	
	ernative methods for valuation	
•	y other information	
E. Capital N	Management	67
E.1 Ow	n funds	67
E.2 Sol	vency capital requirement and minimum capital requirement	69
E.3 Use	e of duration-based equity risk sub-module in the calculation of Solvency Capital	72
E.4 Diff	ference between the Standard Formula and the Internal Model used	72
E.5 Nor	n-compliance with the Minimum Capital Requirement and non-compliance with the	
Solvency C	Capital Requirement	72
E.6 Any	other information	72
Appendix		73

Glossary of Terms

AFSI AmTrust Financial Services Inc.

AIIL AmTrust International Insurance Limited
AIU AmTrust International Underwriters DAC

Board Board of Directors of AIU
CBI Central Bank of Ireland
CEO Chief Executive Officer
CFO Chief Financial Officer
CRO Chief Risk Officer

Company AmTrust International Underwriters DAC

DAC Deferred Acquisition Costs

DTA Deferred Tax Asset

EEA European Economic Area

EIOPA European Insurance and Occupational Pensions Authority

ENID Events Not in Data

ERM Enterprise Risk Management

EXEC Executive Director

GNED Group Non-Executive Director HOAF Head of Actuarial Function

INED Independent Non-Executive Director
Irish GAAP Generally Accepted Accounting Principles

KRI Key Risk Indicator

MCR Minimum Capital Requirement

NED Non-Executive Director

ORSA Own Risk and Solvency Assessment
Own Funds Available capital under Solvency II
PCF Pre-approval Control Function
QRT Quantitative Reporting Template

RAF Risk Authorisation Form

RCC Risk and Compliance Committee SCR Solvency Capital Requirement

SFCR Solvency and Financial Condition Report

SOX Sarbanes-Oxley Act of 2002

TP's Technical Provisions

UPR Unearned Premium Reserve

Executive Summary

Overview of the Business

AmTrust International Underwriters Designated Activity Company ("AIU" or the "Company") is a non-life insurance company headquartered in Dublin, with a branch in Italy.

The Company writes multiple lines of business across the EEA and has a run off portfolio in the US. Its primary lines of business during 2024 were mortgage and credit insurance, commercial credit, warranty, financial lines, payment and income protection insurance, accident and health, professional liability, legal expenses and property.

The Company operates under the EU Solvency II framework and is regulated by the Central Bank of Ireland ("CBI").

The Company is a wholly owned subsidiary of AmTrust Equity Solutions Limited ("AES") which is a company incorporated in Bermuda. The Company is a subsidiary within the AmTrust Financial Services Inc. group. The Company's ultimate parent is Evergreen Parent GP, a United States registered limited liability company.

Solvency II

As a regulated insurance company, the Company is subject to the regulatory rules and principles adopted by Ireland and the European Union, which came into effect on 1 January 2016. Solvency II is a regulatory regime, which is designed to set an appropriate level of capital that appropriately reflects the specific risk profile of insurance companies within the regime.

As an insurance company, the biggest source of risk in the business model relates to the uncertainty around forecasting what the Company's future claims might be for the insurance policies that it has underwritten. Some of these liabilities could be realised many years after the original policy incepted and the associated premium collected. Regulatory capital is designed to act as buffer, which is to be held within the Company's assets and liabilities and provides a safety mechanism to protect policyholders should the Company incorrectly estimate its future liabilities or if unforeseen stressed events occur which impact the markets in which it operates.

This Solvency and Financial Condition Report is a Solvency II requirement produced in accordance with Article 52 of Statutory Instrument 485 of 2015, Articles 290 to 303 of Commission Delegated Regulation (EU) 2015/35 and the EIOPA guidelines on reporting and public disclosure (B0S-15-109). The SFCR is designed to give the Company's customers and stakeholders an insight into the types of business the Company writes, how it manages that business and the overall solvency and financial condition of the Company, including its solvency capital position.

This is the ninth SFCR prepared by the Company and covers the year ended 31 December 2024.

Capital Position and Financial Strength

Under the Solvency II framework, a Company is required to hold sufficient economic capital to withstand the impact of an adverse 1-in-200-year event (or series / combination of events). This is known as the Company's Solvency Capital Requirement ("SCR"). The Company measures its SCR using the Standard Formula and each year obtains independent confirmation that it is appropriate to measure the SCR using this approach.

As at 31 December 2024, the Company's SCR ratio stood at 167% (2023: 160%). The Company's Solvency Capital Requirement stood at €129.2m (2023: €126.8m) and as at that date it had surplus funds of €86.7m (2023: €76.1m).

As a member of the AmTrust Group, the Company benefits from financial, operational and management support. The AmTrust Group is a multinational property and casualty insurance group specialising in small to medium sized businesses. With extensive underwriting experience and a prestigious A-(Excellent) rating from A.M. Best.

Business Strategy and Material Events

The Company is a multinational insurance company offering niche solutions to businesses and their customers. The Company seeks to exceed its stakeholders' expectations by using combined expertise and leadership to deliver market leading, innovative insurance solutions to its clients, with a focus on treating our customers fairly, whilst delivering and supporting the wider AmTrust Group strategy.

The Company focuses predominantly on small commercial business, property, casualty, extended warranty and specialty programmes and mortgage and credit. Working in partnership with its business partners, the Company strives to create a better customer experience with insurance solutions that match clients' and partners' business needs.

From an operational perspective core developments during the year were as follows:

- Appointment of a new Chief Executive Officer in March 2024.
- Payment of €10m in dividends to the Company's parent, AmTrust Equity Solutions Ltd, during 2024.
- Renewal of the reinsurance treaty, "LPT", on historical business with AIIL, an AmTrust Group affiliate domiciled in Bermuda. The LPT was renewed on 30th June 2024 and covers an additional policy set issued by the Company between 1st January 2021 and 31st December 2021.
- Renewal of the 50% Quota Share with Swiss Re which is in place until 30 June 2025 with intention to renew.
- On 26th November 2024, the Company signed a Portfolio Transfer Agreement to acquire a book of non-life insurance business from the French branch of a Belgian insurer. The portfolio to be transferred, subject to regulatory approvals, is comprised of a portfolio of water supply assistance policies.
- On 5th August 2024, the Company accepted a commutation offer from the reinsurer to buy out all existing and future claims on the only remaining French housing surety bonds business not included in the prior 2023 commutation. The commutation releases the reinsurer from the liabilities and obligations arising under the prior quota share agreement.

Business and Performance (Section A)

The table below shows the Profit and Loss Account for the years ended 31st December 2024 and 31st December 2023 under Irish Generally Accepted Accounting Principles ("Irish GAAP").

Income Statement - Irish GAAP	2024 €′000	2023 €′000
Net Earned Premium	108,054	123,725
Net Incurred Claims	(60,290)	(63,393)
Net Operating Expenses	(39,096)	(54,721)
Net Technical Result	8,668	5,611
Allocation of Investment Income	10,769	6,067
Balance of Technical Account	19,437	11,678
Non-Technical Income	719	861
Profit / (Loss) Before Tax	20,156	12,539

The Company's underwriting profit for the year (shown as the Net Technical Result above) was €8.7m compared with €5.6m in the prior year. This was impacted by the following:

- A decrease in net earned premium. Although GWP increased by €55.0m in 2024 over 2023, net earned premium was lower than prior year at €108.1m in 2024 compared to €123.7m in 2023. This is primarily due to higher and expected reinsurance ceding on PPI business.
- An increase in net claims ratio to 56% (2023: 51%). The net cost of claims incurred during 2024 was €60.3m (2023 €63.4m). Core product lines have performed well during the year. Gross Claims decreased during 2024 and primarily driven by ISG claims on US surplus lines and movements in open lending as this has been in run-off since Q1 2023. The increase to the ratio reflects the changes in the level of net premiums earned as outlined above.
- A decrease in net operating expenses, operating costs include acquisition costs and administration costs. The gross acquisition costs have decreased year on year and reflects the lower commission impact due to continued reduction in open lending premium as this is in run off and profit share reductions following a release of reserves in older underwriting years. Gross administration expenses are primarily in line with prior year.

Underwriting performance is reviewed in further detail in Section A.2.

The net investment result was a gain of €10.8m (2023 €6.1m). The Company maintains a high-grade investment portfolio with a primary focus on capital preservation. Further information is included in Section A.3.

System of Governance (Section B)

The Board of Directors of the Company is responsible for the oversight of the management of the Company. Its responsibilities include (but are not limited to) agreeing the Company's strategic direction and objectives, compliance with applicable laws and regulations, ensuring the highest standards of governance are followed and ensuring that the management of the Company is both sound and prudent.

The Company's Board comprises an Independent Non-Executive Chair, three other Independent Non-Executive Directors, two Group Non-Executive Directors and two Executive Directors. The Board meets a minimum of six times a year and additionally as required. Board meetings are held in Dublin at the Company's head office, or by videoconference, as may be required.

The Company employs a "three lines of defence" governance model to ensure that risk management is effective, appropriate decisions are made and best practice is implemented and maintained.

There were no material changes to the system of governance during the year.

Risk Profile (Section C)

The Company calculates its required capital from a regulatory perspective by reference to certain risk categories that it is exposed to within its business model. The main risks to which the Company is exposed are:

- Underwriting risk,
- Market risk, and
- Credit risk.

For each risk category, the Company has articulated how much risk it is willing and able to accept based on its strategic profile and capital position. A company Risk Management System (RMS) has been implemented, containing strategies, processes and reporting procedures necessary to identify, measure, monitor, manage and report on the risks to which we are exposed. The RMS is a component of the overall System of Governance within the company, which provides for sound and prudent management of the business and includes internal control protocols. The Company uses a suite of Key Risk Indicators to monitor its exposure to the various risks to which it is exposed, and these are evaluated on a quarterly basis by the Board Risk and Compliance Committee.

Underwriting Risk

The Company's largest risk exposure is in respect of underwriting risk, which is broken down into two main components: premium risk and reserve risk. Premium risk is the risk that premiums are insufficient to cover the value of claims made; reserve risk is the risk that on-going claims are settled at a higher value than previously expected. The majority of the Company's material underwriting risk exposure comes from Miscellaneous Financial Loss. In addition, other material lines of business in terms of size are Credit & Suretyship and Third-party Liability.

Market Risk

Market risk is the risk of loss of income or decrease in the value of assets caused by movements in the level and prices of financial instruments. Market risk includes factors such as equity values, property values, interest rates, foreign exchange and spread risk.

The Company's material exposures to market risk relate to spread risk on its bond portfolio and foreign exchange risk on its currency exposures. The Company's investment portfolio is predominantly invested in fixed income corporate and government bonds with an average rating of A+ across the portfolio.

Credit Risk

Credit risk is the potential loss arising principally from adverse changes in the financial condition of intermediaries who sell the Company's policies, the issuers of fixed maturity securities and the financial condition of reinsurers.

The Company is subject to material risk exposures with respect to its reinsurers, banks and bond counterparties. The Company is exposed to credit risk in relation to material accounts with reinsurance counterparties.

Other risks

The Company is also exposed to the following other risks:

- Solvency risk;
- Liquidity risk;
- Operational risk;
- Legal and regulatory risk;
- Strategic risk;
- Group risk;
- Governance risk; and
- Reputational risk.

Further information on the Company's risk profile is included in Section C.

Valuation for Solvency Purposes (Section D)

Under Solvency II valuation principles, items in the Company's balance sheet are valued at the amount at which the assets and liabilities could be exchanged between knowledgeable willing parties in an arm's length transaction. This differs from the valuation used in the Company's financial statements, which are valued under Irish GAAP

As at 31 December 2024, the Company's assets less liabilities were valued at €215.9m under Solvency II, compared with €190.6m under Irish GAAP. Further details on the valuation for solvency purposes are included in Section D.

Capital Management (Section E)

The Company's capital management objective is to maintain sufficient capital to safeguard the Company's ability to continue as a going concern and to protect the interests of all its customers, investors, regulators and trading partners while also efficiently deploying capital and managing risk to sustain ongoing business development. The Company maintains a prudent buffer over the SCR.

The Company calculates its SCR using the Standard Formula. In Q4 of 2023, as part of the 2023 ORSA, the Company engaged Willis Towers Watson Limited ("WTW") to assist with an assessment of whether

the Company's risk profile deviated from the assumptions underlying the Solvency II SCR as calculated according to the Standard Formula and whether these deviations were significant. This assessment is required as part of the Company's Own Risk and Solvency Assessment, in accordance with paragraph 1(c) of Article 45 of the Solvency II Framework Directive. Following the timing change of the ORSA to mid-year in 2024, the work completed in 2023 was still considered appropriate for the 2024 ORSA.

Based on the considerations set out in WTW's report, its view is that the Standard Formula provides an appropriate quantification of a one-year 99.5% value-at-risk for the Company, covering all material quantifiable risks to which the Company is exposed and covering existing business, as well as the new business expected to be written over the following twelve months.

The Company does not use any Undertaking Specific Parameters allowed under Solvency II, nor does it use simplified calculations for any of the risk modules.

The table below shows the Company's capital position at 31 December 2024 and 31 December 2023:

Solvency II Capital Requirements	2024	2023
As at 31st December	€'000	€'000
Own Funds	215,851	202,954
Solvency Capital Requirement (SCR)	129,181	126,832
Minimum Capital Requirement (MCR)	32,295	31,708
SCR Coverage	167%	160%
MCR Coverage *	657%	619%
* Eligible Own Funds: MCR €212.3m (2023: €196.2m)		

During 2024 there were no incidences of non-compliance with SCR or MCR requirements.

Information on the SFCR

SFCR Requirements

The Solvency and Financial Condition Report is produced in accordance with Article 52 of S.I. 485 of 2015, Articles 290 to 303 of Commission Delegated Regulation (EU) 2015/35 and the EIOPA guidelines on reporting and public disclosure (B05-15-09). The SFCR is required to be produced and made publicly available on an annual basis.

Article 3 of Commission Implementing Regulation (EU) 2023/895 requires that certain Quantitative Reporting Templates are to be included in the SFCR. These are included in the Appendix to this report.

External Audit

The Company's statutory auditors, EY, have audited the following QRT's:

- S02.01.02 : Balance Sheet
- S12.01.02: Life and Health SLT Technical Provisions
- S17.01.02 : Non-Life Technical Provisions
- \$19.01.21 : Non-Life Insurance Claims Information
- S23.01.01 : Own Funds

EY have also reviewed the narrative sections of this report (Sections D and E.1) for consistency with the related QRTs, in accordance with the Central Bank of Ireland's Requirement for External Audit of Solvency II Regulatory Returns / Public Disclosures.

Materiality

In preparing the SFCR, information disclosed herein is considered to be material where omitting, misstating or obscuring such information could reasonably be expected to influence the decisions or judgment of the users of this document.

Approval

This SFCR report was reviewed and approved by the Board of Directors of the Company on 1st April 2025.

Business and Performance

Section A

A. Business and Performance

A.1 Business Profile

The Company is a non-life insurance Company headquartered in Dublin, Ireland.

As its principal activity, the Company writes non-life insurance business throughout the EEA and has a run-off portfolio in the US. Its primary lines of business during 2024 mortgage and credit insurance, commercial credit, warranty, financial lines, payment and income protection insurance, accident and health, professional liability, legal expenses and property. The Company has a branch in Italy.

AmTrust Financial Services Group

The Company is a wholly owned subsidiary of AmTrust Equity Solutions Limited ("AES") which is a company incorporated in Bermuda. The Company is a subsidiary within the AmTrust Financial Services Inc. Group, "AFSI". The Company's ultimate parent is Evergreen Parent G.P, LLC, a Delaware registered United States limited liability company. Evergreen Parent G.P registered address is Corporation Trust Center, 1209 Orange Street, Wilmington, DE, 19801. AFSI underwrites and provides property and casualty insurance products in the United States and internationally to niche customer groups that it believes are generally underserved within the broader insurance market. As a subsidiary of AFSI the Company benefits from financial, operational and management support. AFSI is a multinational property and casualty insurer specialising in small to medium-sized businesses. With extensive underwriting experience and a prestigious A- (Excellent) Financial Size "XV" rating from A.M. Best, AFSI has earned a reputation as an innovative, technology driven provider of insurance products. Commitment to excellence is a common thread connecting each of the AmTrust companies.

AFSI's business model focuses on achieving targeted returns and profit growth with the careful management of risk. The Global Group pursues these goals through geographic and product diversification, as well as an in-depth understanding of its insured exposure. The product mix includes primarily; workers' compensation, extended warranty, and other commercial property/casualty insurance products, including title insurance. Workers' compensation and property/casualty insurance policyholders in the United States are generally small and middle market businesses. Extended warranty customers are manufacturers, distributors and retailers of commercial and consumer products. AmTrust has also built a strong and growing distribution of extended warranty and specialty risk products in Europe.

The Company, which is licensed in Ireland, writes insurance throughout Europe and the US, offering coverage for non-life insurance in Europe under classes 1, 2, 3, 7, 8, 9, 10, 13, 14, 15, 16, 17 and 18. The Company has a branch in Italy. The Company's core lines of business are Warranty, Mortgage & Credit, Professional Lines, Accident & Health, Property and Legal Expenses insurance. Lines of business in runoff include US Surplus Lines, Structural Defects and Title insurance.

The Company is limited by shares and is wholly owned by AES which is a company incorporated in Bermuda. The company registration number is 169384.

The Company's registered address is as follows:

AmTrust International Underwriters DAC, 6-8 College Green, Dublin 2. D02 VP48.

Tel: +353 (0)1 775 2900

Email: <u>dublin@amtrustgroup.com</u>

A.1.1 Supervisory authority

The Company is regulated by the Central Bank of Ireland. The Central Bank of Ireland's registered address is as follows:

Central Bank of Ireland, New Wapping Street, North Wall Quay, Dublin 1 D01 F7X3

Tel: +353 (0) 1 224 6000 Fax: +353 (0) 1 224 5550

Email: enquiries@centralbank.ie

A.1.2 External auditor


The Company, is audited by EY. EY's Irish office is located at:

Ernst & Young
Chartered Accountants
Block 1,
Harcourt Centre,
Dublin 2,
Ireland.
D02 YA40

Tel: +353 (0) 1 475 0555

A.1.3 Position within the legal structure of the group

The following simplified group structure chart shows where the Company sits within the wider AFSI group.



A.1.4 Material lines of business and material geographical areas where the Company carries out business

The principal activity of the Company is the underwriting of general insurance business in the EEA and the US. The Company's core product lines in 2024 mortgage and credit insurance, commercial credit, warranty, financial lines, payment and income protection insurance, accident and health, professional liability, legal expenses and property.

A.1.5 Material events

During 2024, the Company continued to reposition itself to focus on core territories and lines of business. From an operational perspective other core developments during the year were as follows:

- Appointment of a new Chief Executive Officer in March 2024.
- Payment of €10m in dividends to the Company's parent, AmTrust Equity Solutions Ltd, during 2024
- Renewal of the reinsurance treaty, "LPT", on historical business with AIIL, an AmTrust Group affiliate domiciled in Bermuda. The LPT was renewed on 30th June 2024 and covers an additional policy set issued by the Company between 1st January 2021 and 31st December 2021.
- Renewal of the 50% Quota Share with Swiss Re which is in place until 30 June 2025 with intention to renew.
- On 5th August 2024, the Company accepted a commutation offer from the reinsurer to buy out all existing and future claims on the only remaining French housing surety bonds business not included in the prior 2023 commutation. The commutation releases the reinsurer from the liabilities and obligations arising under the prior quota share agreement.
- On 26th November 2024, the Company signed a Portfolio Transfer Agreement to acquire a book of non-life insurance business from the French branch of a Belgian insurer. The portfolio to be transferred, subject to regulatory approvals, is comprised of a portfolio of water supply assistance policies.



A.2 Underwriting Performance

All values shown in this section are reported on the basis of Irish Generally Accepted Accounting Principles ("Irish GAAP") and are in thousands of Euros (€000).

The table below details the underwriting performance by Line of Business for 2024 and the prior year:

		Misc	ı	Fire and Other			
	General Liability	Financial Loss	Medical Expense	Damage to Property	Credit and Suretyship	Other	Total
Income Statement 2024	€'000	€'000	€'000	€'000	€'000	€'000	€'000
Gross premiums written	21,479	219,644	15,688	8,181	42,369	6,965	314,326
Reinsurers share	(12,866)	(129,532)	(7,882)	(3,988)	(20,600)	(3,418)	(178,286)
Net premiums written	8,613	90,112	7,806	4,193	21,769	3,547	136,040
Gross premiums earned	29,498	201,939	16,427	7,920	49,507	7,342	312,633
Reinsurers share	(21,196)	(125,341)	(8,257)	(3,905)	(41,789)	(4,091)	(204,579)
Net premiums earned	8,302	76,598	8,170	4,015	7,718	3,251	108,054
Gross claims incurred	(68,112)	(107,052)	(2,776)	(4,279)	(6,251)	1,575	(186,895)
Reinsurers share	65,668	58,408	(1,117)	1,806	5,633	(2,219)	128,179
Net claims incurred	(2,444)	(48,644)	(3,893)	(2,473)	(618)	(644)	(58,716)
Net operating expenses	(3,174)	(25,580)	(6,558)	(2,750)	(3,135)	(692)	(41,889)
Net technical result	2,684	2,374	(2,281)	(1,208)	3,965	1,915	7,449

Income Statement 2023	General Liability €'000	Misc Financial Loss €'000	Medical Expense €'000	Fire and Other Damage to Property €'000	Credit and Suretyship €'000	Other €'000	Total €'000
Gross premiums written	21,537	160,397	12,435	5,915	53,529	5,551	259,364
Reinsurers share	(13,946)	(78,816)	(3,955)	(1,986)	(43,717)	(2,099)	(144,519)
Net premiums written	7,591	81,581	8,480	3,929	9,812	3,452	114,845
Gross premiums earned Reinsurers share Net premiums earned	36,817 (27,356) 9,461	169,480 (87,882) 81,598	25,120 (10,897) 14,223	5,482 (1,452) 4,030	65,174 (54,729) 10,445	6,223 (2,255) 3,968	308,296 (184,571) 123,725
Gross claims incurred	(186,931)	(99,415)	(7,855)	(1,802)	(34,977)	(3,580)	(334,560)
Reinsurers share	182,134	51,914	4,794	(253)	31,615	305	270,509
Net claims incurred	(4,797)	(47,501)	(3,061)	(2,055)	(3,362)	(3,275)	(64,051)
Net operating expenses	(4,417)	(27,135)	(14,626)	(2,452)	(3,417)	(2,378)	(54,425)
Net technical result	247	6,962	(3,464)	(477)	3,666	(1,685)	5,249

^{*}Note the above table is presented per S.05.01. This QRT includes the ALEA in net operating expenses whereas the financial statements include the ALEA in claims incurred. The ratios in the following section are based on the numbers presented in the above table.

Gross written premium levels increased by 21% to €314.3m (2023: €259.4m). The net increase in written premium was largely driven by growth in our Payment Protection and Warranty business.

Gross earned premiums increased slightly mainly driven by the increase in written premium year-on-year within Miscellaneous Financial Loss, however net earned premium was lower than prior year at €108.1m in 2024 compared to €123.7m in 2023. This is primarily due to higher and expected reinsurance ceding on PPI business.



The Company's net claims ratio increased during the year to 54% (2023: 52%). The net cost of claims incurred during 2024 was lower at €58.7m (2023 €64.1m). The increase to the ratio reflects the changes in the level of net premiums earned as outlined above. Overall, the core product lines have generally performed well during the year. Gross claims decreased during 2024 primarily linked to an improvement within General Liability and Credit and Suretyship.

During 2024 all lines of business had positive underwriting profits (pre operating expense allocation). The Board acknowledges that the Company is a significant net contributor to the shareholder by means of its internal group cessions and the use of internal group MGA's who receive commissions for directing business to the Company and is satisfied with the overall profitability of the company.

The Company's combined ratio has decreased during the year to 93% (2023: 96%).

- o This was driven by a 5% decrease in expense ratio. The expense ratio has decreased as actual expenses have decreased year on year to €41.9m in 2024 compared to €54.4m in 2023. Operating costs include acquisition costs and administration costs. The gross acquisition costs have decreased year on year and reflects the lower commission impact due to continued reduction in open lending premium as this is in run off and profit share reductions following a release of reserves in older underwriting years. Gross administration expenses are primarily in line with prior year.
- o The above was partially offset by an 2% increase in claims ratio. Although net claims reduced in 2024 to €58.7m (2023: €64.1m) the increase in ratio reflects the changes in the level of net premiums earned as outlined above.

A.2.1 Material lines of business

A.2.1.1 Miscellaneous financial loss

Warranty

The key covers provided within this segment are consumer electronics, home emergency, plant and equipment and auto warranty.

The consumer electronics business segment includes cover in respect of mobile phones, tablets, televisions, white goods, computers and other portable items.

The warranty business has performed consistently well over a number of years. The Company has extensive experience in this line of business in both the Nordic and continental European markets.

Payment Protection Insurance (PPI)

The payment protection segment continues to perform well. This includes income protection business which covers the loss of salary due to unemployment or bankruptcy for self-employed individuals, and payment protection covering an inability to make contractual payments connected to credit cards, loans, etc. Currently this business is primarily focused on the Nordic region and adjacent territories and mainly sourced through broker channels.

A.2.1.2 Credit & Suretyship

Mortgage Insurance

Mortgage insurance covers the credit default risk for lenders of residential mortgages. Premiums are paid by the lenders (rather than the consumer) who are the insured party. Product offerings include

'Flow' insurance which provides prospective cover on a loan-by-loan basis and 'Structured/In Force' insurance, which provides cover to a portfolio of pre-existing loans. To date this business has been sourced via a partnership with Qualis Europe S.r.l, an affiliated AmTrust entity domiciled in Italy.

Commercial Credit

The Company operates a large commercial credit programme in the United States focused on offering protection to small and medium sized financial institutions in respect of auto loans. In the case of repossession and sale of the collateral vehicle, the insurance will reimburse the lender for a portion of the difference between the outstanding loan balance and the auction proceeds. The coverage has a loss limit per loan and requires the lender to attempt to prevent defaults as well as taking any appropriate actions / subrogation's prior to making a claim. This book has continued to contract during 2024, as new business writings have previously transitioned to alternative AmTrust Group insurance companies domiciled in the US.

Surety

Following the divestiture of the National Borg Surety business through a Group transaction with Liberty Mutual during 2019 and the subsequent portfolio transfer of this business during 2020, the Company's involvement in the Surety line of business significantly decreased in 2020 and continues to reduce year-on-year. The Company continues to write a small and declining select book of Spanish surety business.

A.2.1.3 General Liability

Financial Lines

This segment relates to financial lines products mainly driven by Directors and Officers Liability, Mergers and Acquisitions insurance and other Professional Liability products.

General Liability

The Company historically wrote general liability and professional indemnity business in the US and this business is in run-off. All US surplus lines liabilities are fully reinsured with AmTrust Group affiliates.

A.2.1.4 Medical Expenses

Accident and Health

The Company offers several insurance products within this segment mainly driven by Medical and Dental insurance with elements of Personal Accident and Travel covers also included.

A.2.1.5 Fire and Other Damage to Property

The Company underwrites a portfolio of commercial and personal property insurance in the EEA. Coverage includes commercial property, household and residential lettings business. Distribution is typically via the broker market.



A.2.1.6 Other

Other Business Lines comprise mainly of Legal Expenses insurance, non-proportional property reinsurance and Income protection insurance.

A.2.2 Material geographic areas

Performance in the top five countries, based on GWP, in which the Company operates is summarised in the table below. The Company's changing geographic footprint reflects the Company's focus on our core products and EU territory. The inclusion of Poland and Germany below in 2024 is driven by an increase in our Warranty and Payment Protection business in these countries respectively. The year-on-year reduction in our US book reflects the run-off nature of this business.

	France	Poland	Denmark	Sweden	Germany	Other	Total
Income Statement 2024	€'000	€'000	€'000	€'000	€'000	€'000	€'000
Gross Written Premium	35,885	45,251	38,026	48,910	46,640	99,614	314,326
Net Earned Premium	17,368	7,718	18,472	23,834	7,136	33,526	108,054
Net Claims Incurred	(15,284)	(3,807)	(12,115)	(9,216)	(3,115)	(15,179)	(58,716)
Technical expenses	1,244	363	504	(9,286)	(1,405)	(33,309)	(41,889)
Underwriting result	3,328	4,274	6,861	5,332	2,616	(14,962)	7,449

	Italy	France	USA	Sweden	Denmark	Other	Total
Income Statement 2023	€'000	€'000	€'000	€'000	€'000	€'000	€'000
Gross Written Premium	22,823	33,541	33,269	47,884	37,080	84,767	259,364
Net Earned Premium	11,791	16,690	273	32,237	20,976	41,758	123,725
Net Claims Incurred	(4,506)	(14,228)	(344)	(13,697)	(10,140)	(21,136)	(64,051)
Technical expenses	2,102	(286)	(5,198)	(10,515)	(4,038)	(36,490)	(54,425)
Underwriting result	9,387	2,176	(5,269)	8,026	6,798	(15,868)	5,249

A.3 Investment Performance

The Company invests predominantly in corporate and government bonds. The management of the bond portfolio is outsourced to another company within the Group, AFSI, which has a dedicated team of investment managers. A set of investment management guidelines has been drawn up, adherence to which is monitored by the Investment and Capital Management Committee.

The Company also owns its branch office building in Milan, Italy.

Investment Income and expenses during the year are shown in the table overleaf.



Investment Income 2024	Net Investment Income €'000	Net Investment Expense €'000	Net Realised Gain/(Loss) €'000	Changes in Fair Value €'000	Total €'000
Debt Securities	3,994	-	98	10,056	14,148
Shares	-	-	-	-	-
Receivables	-	-	(13)	-	(13)
Cash and cash equivalent	616	-	287	(104)	799
Interest paid on funds withheld	-	(3,715)	-	-	(3,715)
Investment manager charges	-	(450)	-	-	(450)
Total	4,610	(4,165)	372	9,952	10,769

	Net Investment Income	Net Investment Expense		Changes in Fair Value	Total
Investment Income 2023	€′000	€′000	€′000	€′000	€′000
Debt Securities	3,769	-	(2,960)	12,889	13,698
Shares	-	-	-	-	-
Receivables	-	-	37	-	37
Cash and cash equivalent	119	-	410	118	647
Interest paid on funds withheld	-	(7,349)	-	-	(7,349)
Investment manager charges	-	(966)	-	-	(966)
Total	3,888	(8,315)	(2,512)	13,007	6,067

The net investment result was a gain of €10.8m (2023: €6.1m). Investment income consists of income earned from financial investments and investment expenses. The movement of €4.7m year on year is largely related to lower net investment expenses in particular interest paid on funds withheld. The Company maintains a high-grade investment portfolio with a primary focus on capital preservation.

A.4 Performance of other activities

The Company did not undertake any other activities during the year.

A.5 Any other information

None noted.



System of Governance

Section B



B. System of Governance

B.1 General information on the system of governance

B.1.1 The Board and System of Governance

The Company recognises that its governance arrangements should be comprehensive and proportionate, taking into consideration the nature, scale and complexity of the entity and its link with AmTrust Group. The Company has developed a system of corporate governance to ensure that there is clear decision making, combined with accountability and transparency.

The CBI's Individual Accountability Framework ("IAF") introduced new requirements for regulated financial services providers designed to raise standards of governance, promote good behaviour and help restore consumer confidence in the financial services sector. The Company has undertaken a range of preparatory activities, including:

- In person training for all Controlled Functions (CF) on the principles of the IAF and specifically on the new Common Conduct Standards.
- Additional in person training for the Pre-Approval Controlled Functions (PCF) and CF1s on the Additional Conduct Standards.
- Updated the Fitness and Probity policy, procedures and certification templates and introduced a new Conduct Standards and Breach Reporting policy.

The above enhancement activities were completed to meet the requirements of the Conduct Standards which applied from 29th December 2023 and the Certification Regime which applied from 8th January 2024.

At the heart of the IAF is the Senior Executive Accountability Regime (SEAR) which requires firms to set out clearly where responsibility and decision-making lies for their business.

The SEAR applies to Executive PCF roles for in-scope firms from 1st July 2024, with Non-Executive roles in scope from 1st July 2025.

In meeting the 1st July 2024 deadline, the Company has:


- Documented its key management and governance arrangements in a Management Responsibilities Map (MRM).
- Created a Responsibilities Matrix as part of the MRM which identifies the individuals in PCF roles and the allocation of all Inherent, Prescribed and firm agreed Other Responsibilities to these roles.
- Identified significant delegations where there is key reliance for the performance of significant Activities.
- Completed and issued individual Statements of Responsibility for all Executive PCF roles.

Further completed activities into 2025 include:

- Issuing the individual Statements of Responsibility for Non-Executive PCF roles when SEAR applies on 1 July 2025;
- Assessing the requirements of the Business Standards which are being developed in conjunction with the separate review of the Consumer Protection Code.

The IAF remains a key cross functional project which will continue to be a focus for management, and the Board will continue to be regularly updated on its implementation and developments.

The Company has established a well-defined governance framework, system of control and committee structure. The Board and its sub-committees are shown in the diagram below.



The Company employs a "three lines of defence" governance model to ensure that risk management is effective, appropriate decisions are made and best practice is implemented and maintained. Broadly, the responsibility of the three lines is as follows:

- First Line of Defence undertakes the primary risk taking and decision-making activities. It represents the bulk of the Company's people, systems and controls that are integral to achieving the Company's strategy. The senior manager is responsible for the identification and assessment of risks and controls in their relevant area, as well as for developing and implementing mitigation plans where necessary.
- Second Line of Defence is responsible for reviewing risks across the first line. No risk-taking activities take place here. Key control functions such as Risk Management, Compliance and IT Risk & Security sit within this line of defence which are independent of personnel responsible for originating risk exposures. The Risk function provides support and challenge the completeness and accuracy of risk assessments and the adequacy of mitigation plans. The Compliance function is responsible for ensuring that the Company complies with applicable laws, and regulations as well as supporting business in designing new controls through review of control framework and recommendations from monitoring and testing.
- Third Line of Defence the first and second lines together form the Company's system of governance and internal control. The Third Line is independent of first and second lines, and its primary objective is to provide assurance on the robustness of the risk management framework and the appropriateness and effectiveness of the Company's governance and internal control systems. The Company has an independent Internal Audit function which resides in this line of defence.

B.1.1.1 Board responsibilities

The Board comprises an Independent Non-Executive Chair, three other Independent Non-Executive Directors, two Group Non-Executive Director and two Executive Directors. The Board comprises individuals with a broad set of qualities and competencies and a diverse mix of skills and experience which enables individual Board members to effectively fulfil their specific Board remit and to provide effective challenge across the full range of the firm's business activities and explore key business issues rigorously. Ensuring the capability, capacity and opportunity of the Board to do so facilitates proper Board effectiveness and sound decision making.

It meets at least six times a year and additionally as required. Minutes of all Board and committee meetings are recorded and reflect the substance of the discussion, as well as the decisions made.

The Board closely monitors developments in corporate governance and assesses how these can be applied to the Company. The Company's governance arrangements continue to be reviewed in line with developments in best practice and as required by the CBI's Corporate Governance Requirements for Insurance Undertakings 2015 (the "Requirements") and Central Bank (Individual Accountability Framework) Act 2023. The Board believes the existing structure is appropriate for the size, nature and complexity of the Company.

The Board is responsible for all activities undertaken by the Company, including outsourced activities where the activities are conducted on the Company's behalf by any third party, including any group entity. In particular, the Board is responsible for, among other things, where relevant, reviewing and/or setting and overseeing:

• the appointment of people who may have a material impact on the risk profile of the Company and monitoring on an on-going basis their appropriateness for the role.

- documenting the responsibilities of the Board, Board committees and senior management to ensure that no single person has unfettered control of the business.
- that all key control functions such as internal audit, compliance, actuarial and risk management are independent of business units, and have adequate resources and authority to operate effectively.
- the business strategy for the Company.
- the amounts, types and distribution of both internal capital and own funds adequate to cover the risks of the Company.
- the strategy for the on-going management of material risks in accordance with the Requirements and all other applicable statutory and regulatory requirements.
- a robust and transparent organisational structure with effective communication and reporting channels.
- a remuneration framework that is in line with the risk strategy of the Company; and
- an adequate and effective internal control framework, reflective of the Company's risk appetite, which includes well-functioning risk management, compliance and internal audit functions as well as an appropriate financial reporting and accounting framework.

B.1.1.2 The role of the Chair

The Chair is responsible for the leadership of the Board and is pivotal in the creation of the conditions necessary for overall Board and individual director effectiveness, both in and outside the boardroom, including:

- The leadership of the Board, encouraging critical discussions, challenging mind-sets and promoting effective communication between the executive and non-executive directors.
- Ensuring effective Board and committee governance.
- Setting agendas.
- Ensuring that members of the Board receive accurate, timely and clear information.
- Managing the Board to ensure sufficient time is allowed for discussion of key risks and issues.
- Facilitating contributions from INEDs.
- Considering and addressing the development needs (induction, training and professional development) of individual directors and the Board as a whole.

B.1.1.3 The role of the Independent Non-Executive Directors

The role of the Independent Non-Executive Directors includes the following key elements:

- An independent viewpoint and challenge to the deliberations of the Board that is objective and independent of the activities of the management and of the insurance undertaking.
- A knowledge and understanding of the business, risks and material activities of the insurance undertaking to enable them to contribute effectively.
- Constructive challenge and helping to develop proposals on longer-term direction and strategy.
- Scrutiny of the performance of management in meeting agreed goals, objectives, and monitoring the reporting of performance.

• Ensuring the integrity of financial information and that financial controls and systems of risk management are robust and effective.

B.1.1.4 The role of the Non-Executive Directors

The role of the Group non-executive director is to:

- ensure that there is an effective executive team in place.
- participate actively in constructively challenging and developing strategies proposed by the executive team.
- participate actively in the Board's decision-making process.
- participate actively in Board committees; and
- exercise appropriate oversight over execution by the executive team of the agreed strategies, goals and objectives and to monitor reporting of performance.

B.1.1.5 The role of the Chief Executive Officer

The Chief Executive Officer ("CEO") manages the Company in accordance with the strategy and business plans approved by the Board. The CEO leads the development of the Company's business strategy for proposal to the Board and its execution following approval by the Board. The CEO is accountable for:

- Ensuring that the Company maintains a sufficient solvency margin and that customers are treated fairly.
- Ensuring that the Company is compliant with all laws and regulations affecting its business, its policyholders and its staff, including fulfilling all relevant obligations as required under the Central Bank's Fitness and Probity Regime.
- Managing the Company's risk profile, in line with the extent and categories of risk identified as acceptable by the Board.
- Approving the apportionment and allocation of roles and responsibilities of the executive management team of the Company.
- Approving all capital and revenue transactions, including acquisitions and disposals, not specifically reserved to the Board.

B.1.1.6 The Role of the Executive Director

The executive directors shall comprise individuals with relevant skills, experience and knowledge (such as accounting, auditing and risk management knowledge, where appropriate).

The role of the executive director is to

• includes the proposal of strategies to the Board and, following Board scrutiny, to execute the agreed strategies to the highest possible standards.

At year-end 2024, the Board of Directors consisted of eight members, including the Chair of the Board as follows:

Board Member	Board Balance	Key Role
Chair of the Board	Independent	Chairing the Board, member of Remuneration & Nomination Committee.
Independent Non-Executive Director	Independent	Chairing the Audit Committee, chairing the Remuneration and Nomination Committee and member of Risk and Compliance Committee
Independent Non-Executive Director	Independent	Chairing the Risk & Compliance Committee, member of Audit Committee
Independent Non-Executive Director	Independent	Member of Audit Committee, member of Risk and Compliance Committee and member of Reserving Committee
Group Non-Executive Director	Group Role	Member of Remuneration & Nomination Committee
Group Non-Executive Director	Group Role	
Chief Executive Officer	Executive	Member of Risk & Compliance Committee, Member of Reserving Committee, Member of the Investment and Capital Management Committee, day-to-day running of the Company
Chief Finance Officer	Executive	Chair and Member of the Investment and Capital Management Committee, Member and Chair of the Reserving Committee, finance operations of the Company.

B.1.1.7 First Line Committees

Remuneration and Nomination Committee

The Remuneration and Nomination Committee is appointed by the Board and comprises three members: the Chair of the Committee who is an independent Non-Executive Director, a Group Non-Executive Director and the Chair of the Board. The Chief Executive Officer, Group Head of Human Resources of AmTrust International and General Counsel are regular attendees at meetings.

The Committee Chair is responsible for overseeing the performance of the Committee and the oversight of the development and implementation of the Company's remuneration policies and practices.

The Committee reports on executive compensation; reviews successions and leadership plans for all Executive Management; approves remuneration and compensation policies and approves compensation arrangements for Executive Management and the Chief Executive Officer and as



otherwise set out in its Terms of Reference. In addition, the Committee is responsible for considering any proposed Pre-Approval Controlled Functions in line with Fit and Proper requirements for approval by the Board. The Committee ensures that the Company's remuneration practices do not promote excessive risk-taking. The Committee does not have authority to determine the pay of the Non-Executive Directors of the Board.

The Committee reviews the structure, size and composition (including the skills, knowledge, experience and diversity) of the Board and makes any consequential recommendations to the Board. The Committee has established and maintains a Board Diversity Policy. The Committee gives full consideration to succession planning for directors and other senior executives in the course of its work, taking into account the challenges and opportunities facing the Company, and the skills and expertise needed on the Board in the future.

Reserving Committee

Setting adequate reserves for policies underwritten represents the largest risk to an insurance company. The key purpose of the Reserving Committee is to ensure appropriate reserving processes are in place at the Company and that the level of reserves booked by the Company is reasonable. The key responsibilities of this committee are to determine and recommend reserving levels for the business underwritten by the Company, ensure the reserving process is effective in providing the Board with the agreed level of comfort that the reserves in the Financial Statements are appropriate and to ensure that the Solvency II technical provisions are appropriate.

The Company maintains an Actuarial function that projects an independent actuarial estimate of the reserves for each class of business. These are presented and reviewed at the Reserving Committee to challenge management's view of the reserves. The discussions and changes to reserves are formally minuted.

The Reserving Committee comprises six members: the Chief Executive Officer, Chief Finance Officer, the Head of Underwriting, the Head of Claims, the Head of Actuarial Function and an Independent Non-Executive Director.

Underwriting Committee

The key purpose of the Underwriting Committee is to monitor and manage performance against the business plan and the associated insurance risk. The key responsibilities of this committee are to review the Company's underwriting policies, guidelines, authorities, processes and procedures to meet its underwriting risk appetite; review underwriting performance; and assess the Company's underwriting opportunities within its chosen markets.

The Underwriting Committee comprises five members: the Chief Executive Officer, the Head of Underwriting, the Chief Risk Officer, the Head of Claims and the Senior Technical Underwriter. The Head of Compliance is a regular attendee at meetings. The Chair may request individual Company underwriters or other staff members to attend meetings, as and when required.

Investment and Capital Management Committee

The key purpose of the Investment and Capital Management Committee is to monitor investment risk and associated credit and liquidity risk, review the credit quality of collateral, monitor capital results and forecasts and to review Solvency II quantitative reporting.



This Committee comprises five members: the Head of Investments, Chief Executive Officer, Head of Actuarial Function, Chief Risk Officer and Head of Capital Management.

Executive Management Team Committee

The key purpose of the Executive Management Team Committee is to assist and advise the CEO in the management of the Company within the bounds of the authority granted to the CEO by the Company's Board of Directors, including:

- the development and implementation of strategy, operational plans, policies, procedures and budgets.
- monitoring of operating and financial performance.
- monitoring of outsourced activities
- assessment and control of risk.
- the assessment and review of the control environment.
- assessment and control of the Company's branches.
- governance of relevant sub-committees; and
- the prioritisation and allocation of resources.

The Committee comprises the Chief Executive Officer, Chief Finance Officer, Chief Risk Officer, Head of Compliance, Chief Operations Officer, Head of Underwriting, Head of Claims and General Counsel

Claims Committee

The key purpose of the Claims Committee is to ensure there is adequate oversight of claims across all lines of business and jurisdictions. Responsibilities of the Committee include reporting and reviewing claims trends, large losses and any claims issues across all lines of business and jurisdictions and approving case reserve movements in line with claims authority limits.

The Committee comprises five members: the Chief Executive Officer, Chief Finance Officer, the Head of Underwriting, the Chief Risk Officer and the Head of Claims. The Head of Compliance, an Actuarial Manager and Claims Team Lead are regular attendees at meetings. The Chair may request other staff members to attend meetings as and when required.

Outsourcing/ Delegated Oversight Committee

The key purpose of the Outsourcing/ Delegated Oversight Committee is to provide governance, oversight, and advice/recommendations to the Executive Management Team on matters relating to all outsourcing arrangements with third party and intragroup outsourcing service providers. This Committee is also responsible for monitoring and reviewing the effectiveness of the internal controls required to manage outsourcing risk. The Committee is chaired by the Head of Delegated Oversight and its membership is made up of representatives from each business unit including claims, underwriting, credit control, outsourcing, risk and compliance.

Recovery Steering Committee

The Company's Recovery and Resolution Plan identifies the process and timing for the establishment of a Recovery Steering Committee. It is chaired by the Chief Risk Officer and other members include the CEO, Chief Financial Officer and Head of Legal. The Committee meets pursuant to certain defined trigger events referred to within the Company Recovery and Resolution plan.

Data Governance Committee

The key purpose of the Data Governance Committee is to promote data quality and governance across the Company and to contribute to the promotion of data quality and governance across the AmTrust Group.

The Committee is chaired by the Chief Operations Officer of the Company and comprises members of the executive management teams from the Company and AmTrust Specialty Limited representing various business units within the Company.

Reinsurance Deal Review Committee

The key purpose of the Reinsurance Deal Review Committee is to review and approve new/renewal quota share or excess of loss reinsurance arrangements impacting the Company and AmTrust Specialty Limited.

The Committee is chaired by the AmTrust International CFO and members from the Company include the CEO, CFO, CRO and Head of Underwriting.

B.1.1.8 Second Line Committees

The Risk & Compliance Committee

The key purpose of the Risk & Compliance Committee in relation to Risk Management is:

- Overseeing and advising the Board on the current risk exposures of the Company and future risk strategy to ensure that the interests of its shareholders and customers are properly protected through the application of effective risk and capital management frameworks.
- Advising and making recommendations to the Board on:
 - 1. Risk appetite and tolerance for future strategy, taking into account the Board's overall risk appetite, the current financial position of the Company and, drawing on the work of the Audit Committee and the External Auditor, the capacity of the Company to manage control risks within the agreed strategy.
 - 2. The system and programme of risk management with the aim of identifying, measuring, controlling and reporting risks.
 - 3. The Company's risk management and compliance framework in order to establish that the First and Second Lines of Defence are efficient and effective and that the business complies with applicable laws and regulations.
 - 4. The alignment of strategy with the Board's risk appetite; and
 - 5. Promoting and embedding a risk awareness culture within the Company.

The key purpose of the Committee in relation to Compliance is:

- Overseeing and advising the Board on the current compliance exposures of the Company and ensuring implementation of the annual Compliance Plan.
- Reviewing the Company's systems and controls around prevention and detection of, antimoney laundering, financial sanctions and bribery in accordance with regulatory requirements.
- Promoting and embedding a culture of compliance and ethical behaviour.
- Ensuring that the Compliance function is adequately resourced.



The Committee is appointed by the Board and comprises the Chair of the Committee who is an independent Non-Executive Director, the Chief Executive Officer and two independent Non-Executive Directors. The Chief Risk Officer, the Head of Compliance, General Counsel and the Chief Financial Officer are regular attendees at meetings.

B.1.1.9 Third Line Committee

Audit Committee

The key purpose of the Audit Committee is to assist the Board of the Company in fulfilling its statutory and fiduciary responsibilities relating to the external reporting of financial information, internal controls and the independence and effectiveness of internal and external audits.

The key responsibilities of the Committee are to monitor the financial reporting process; to inform the Board of the outcome of the statutory audit; to make a recommendation for the appointment of the audit firm; and to review the appropriateness of the Company's Internal Audit function, internal data, systems, controls, and risk management as related to financial reporting.

The Committee is appointed by the Board and comprises three Independent Non-Executive Directors of the Board. The Chief Finance Officer, Chief Risk Officer, the Head of Compliance, General Counsel, Head of Internal Audit and external auditors are regular attendees at meetings.

B.1.2 Changes in the System of Governance [Changes to Directorships, Committee structures]

During 2023, the CEO resigned and the General Counsel took over the CEO role on an interim basis until a replacement CEO was found. The new CEO commenced in that role on 11 March 2024. The General Counsel retained the role of Company Secretary and a joint Company Secretary was also appointed.

During 2024, the Outsourcing Committee was renamed the Delegated Oversight Committee and the Third Party Due Diligence Committee was merged into the Delegated Oversight Committee.

B.1.3 Remuneration Policy

The Remuneration & Nomination Committee reports to and has delegated authority from the Board to ensure that the Company has a business appropriate, Board approved Remuneration Policy that is compliant with applicable regulations. The Remuneration & Nomination Committee is responsible for the oversight of its implementation by the management of the Company and is authorised to review and approve the remuneration plans and programmes that fall within the Remuneration Policy. It is authorised to review and approve all payments and awards pursuant to the remuneration plans at either an aggregate or individual employee level as designated by the Remuneration Policy and the Remuneration & Nomination Committee's Terms of Reference

The Remuneration Policy describes the overarching principles and framework for the employees that fall within its scope and operate on its behalf. In that regard the Remuneration Policy follows the requirements contained within the CBI's Corporate Requirements for Insurance Undertakings 2015 (the "Corporate Governance Requirements"). The Company's Board is responsible for the effective, prudent and ethical oversight of the insurance undertaking and inter alia is responsible for setting and overseeing a remuneration framework (via the Remuneration & Nomination Committee) that is in line with the risk strategies of the Company.



The Remuneration Policy is designed to support the appropriate management of employee compensation and act as reference for the Board, Remuneration & Nomination Committee, and Management when making decisions on pay. The Remuneration process and the associated remuneration plans and programmes will be regularly reviewed by the Committee to ensure that they remain fit for purpose in terms of business strategy and applicable regulations. The process is designed to:

- Help to attract, retain and motivate competent, experienced and skilled personnel.
- Be competitive within the general insurance market.
- Encourage and support a high-performance culture.
- Be consistent, fair and transparent.
- Achieve a balance between short and long-term reward/fixed and variable pay to promote a long-term focus.
- Promote sound and effective risk management to prevent excessive risk taking that exceeds the risk appetite / tolerance limits.
- Ensure that incentives are aligned, particularly in relation to decision-making and risk-taking behaviour, with the Company's overall business and risk management strategies and objectives.
- Avoid rewarding failure.
- Consider the overall assessment of an individual's performance, not just the performance of the Company or a particular business unit; and
- Particularly in the case of senior managers, be aligned to the Shareholders' interests.

The Company aims for the following in respect of its remuneration practices:

- Provide market competitive pay, typically aimed at market median for the business sector, role
 and location of the relevant employees; Individual pay rates may fall above or below market
 median based upon experience, tenure and performance in a role as well as the market supply
 and demand for a particular skill set.
- Enable the Company to attract and retain the right talent for the business at a business appropriate and sustainable cost.
- Provide market appropriate pay structures that include a role appropriate level of fixed and variable pay in line with market norms and an appropriate benefit programme.
- Ensure that pay programmes are aligned to the Company's business strategy, risk appetite statements, codes of conduct and applicable regulations and reward only appropriate behaviour. Ensure that both short and long-term performance is taken into consideration as appropriate; and
- Ensure the appropriate governance and independence as it relates to pay decisions and the appropriate scrutiny as it relates to key employees including those designated as Solvency II employees.

INED fees are reviewed on a periodic basis and if roles or duties materially change. The Company's policy is to pay sufficient fees to attract INEDs with the necessary skills and experience to provide effective input to the Board. In practice, fees are usually targeted at the market median for companies of similar business and size. Reviews will be conducted by the designated Group resources.



The Company aims for the following in respect of variable pay:

- Variable pay and the associated programmes and awards are structured according to the nature of the role and its position within the business.
- Fixed and variable pay are broadly aligned to market norms, with a sufficiently high proportion of pay delivered in fixed base pay as relevant to remit and seniority.
- The proportion of pay delivered through variable remuneration generally increases with seniority within the organisation. This reflects the increased ability to impact the success of the organisation with increased seniority and is in line with general market practice.
- Variable pay awards are designed to take into consideration both individual and business
 performance (financial and non-financial) as appropriate for the role with assessment
 (including values-based competencies) and reward frameworks designed to drive desired
 behaviours, including advancing the Company's culture, risk management and complying with
 the requirements of the applicable regulatory regimes.
- All variable pay programmes allow for no awards to be made based upon either individual and/or business performance;
- The variable pay structures ensure that AmTrust's senior employees are aligned not only to the annual goals but also to the long-term success of the relevant business and the AmTrust Group through deferral and long-term incentive arrangements linked to AmTrust Group performance over a multi-year period, typically three years; and
- All programmes allow flexibility and discretion to ensure alignment to risk and performance of
 the business with provisions (as applicable to the business and/or population) enabling
 management and the Committee to make a downward adjustment to proposed awards at
 either aggregate or individual level in line with the performance of either the individual or
 business and increased exposure to current or future risk. Management or the Committee may
 also prevent the vesting of some or all a deferred award in the event of proven misconduct or
 significant risk management failure.

B.1.4 Pension scheme

Executive Director Board members are entitled to join a workplace pension scheme. The Company does not provide any supplementary pension to its Non-Executive Directors.

The Company provides a workplace pension scheme where all eligible members are automatically enrolled into the scheme and non-eligible or entitled workers can opt in to join the scheme or enroll in a Personal Retirement Savings Account ("PRSA"). The pension scheme is a Group Flexible Retirement Plan, which is designed to give members flexible ways to save for retirement. Both the employer and employee make contributions.

B.1.5 Material transactions with shareholders, persons with significant influence and Board members

The Company has had no material transactions with shareholders, persons with significant influence or members of Board during the reporting period.



B.1.6 Adequacy of the system of governance

The Board is satisfied that the system of governance of the Company is adequate to the nature, scale and complexity of the risks inherent in its business. The Company undertook an external Board effectiveness review in 2024 and will seek to implement its recommendations during 2024 and 2025.

B.2 Fit and Proper Requirements

The Company is committed to employing individuals with the necessary skills, expertise and integrity to fulfil the role, duties and responsibilities for which they are employed to protect the interests of the policyholders, shareholders and other stakeholders.

The CBI mandates that individuals performing Pre-Approval Controlled Functions (PCF), or Controlled Function (CF) roles remain fit and proper to undertake the role. CBI regulations provide for a comprehensive list of PCF roles, including but not limited to the Board of Directors and CEO, all of which must be pre-approved by the CBI before they can take up a PCF position. The Company has a Fitness and Probity Policy and Procedure in place that outlines the various checks at recruitment and throughout employment. When deciding whether a person meets the Fitness and Probity Standards (Code issued under Section 50 of the Central Bank Reform Act 2010) required to full their remit and the associated aspects of the Company's affairs and accordingly is assessed fit and proper the Company satisfies itself that the individual:

- has the personal characteristics (including being financially sound and of good repute and integrity,
- possesses the requisite level of competence, knowledge, experience and the qualifications to undertake the role, and
- has undergone or is undergoing all the training required, to enable such person to perform his or her key function effectively and in accordance with any relevant regulatory requirements and to enable sound and prudent management of the Company,
- meets the ongoing performance requirements of his or her key function, including the designated Inherent, Prescribed and any Other Responsibilities for PCF role holders,
- meets the core Company behavioural and professional competency standards and values.

When deciding whether the Board is fit and proper, the Company seeks to ensure that the Directors collectively possess appropriate qualifications, experience and knowledge about at least:

- insurance and financial markets,
- business strategy and business model,
- systems of governance,
- financial and actuarial analysis, and
- regulatory framework and requirements.

Fitness and probity are checked at recruitment stage through appropriate due diligence checks and challenge of an individual's curriculum vitae ("CV"). Appropriate fitness and probity checks are carried out prior to recruitment of an individual, including qualifications, references, conduct and financial soundness checks, and probation periods are set commensurate with the role. Ongoing assessment of fitness and probity of all Company employees is through the annual appraisal process and in relation to CF role holders through annual assessment of their continued compliance with the Fitness and

Probity Standards, and ongoing screening to ensure there has been no change in circumstance that may affect their fitness or probity to perform their role. Performance of the Board is also assessed through the Board performance review process.

Pursuant to the enhancements to the current Fitness & Probity Regime under IAF and the Company's enhanced procedures to proactively certify that individuals carrying out PCF and CF functions are fit and proper and capable of performing their roles with integrity and competence; from 1 January 2025, the Company will submit an annual PCF Confirmation and a CF Certification to the Central Bank of Ireland.

B.3 Risk management system including the own risk solvency assessment

B.3.1 Risk Management Strategy

The Risk Management Strategy sets out the Company's approach to identifying, assessing and mitigating risks that could impact on our Company's objectives. The Board is ultimately responsible for ensuring the effectiveness of the risk management system, setting the Company's risk appetite and approving the main risk management strategies and policies. The Risk Management Function (RMF) function co-ordinates risk management activities within the Company through the Risk Management framework, which consists of procedures to identify, measure, manage, monitor and report risk.

B.3.2 The Risk Management Process

The risk management process at the Company begins with the strategy and business plan. Risk appetites are then defined to determine how much risk the Company is willing to take in pursuit of our strategic objectives. Using top-down and bottom-up risk assessment tools, the RMF supports the business to identify, measure, monitor, manage and report, on a continuous basis the risks, at an individual and at an aggregated level, to which they are or could be exposed,

Risks are identified, measured, managed and monitored through a top-down Top Risks and Emerging Risk process and a bottom up RCSA process, the RCSA's focusing on the operational related risks of the company. Regular reporting against the risk appetite is conducted through a set of carefully selected risk appetite key risk indicator metrics, which inform the Board. The operating effectiveness of controls is assessed by both the front-line functions and independently through audit, monitoring and other oversight activities performed by Risk, Compliance, Internal Audit or External Audit. Annual formal assessments of the Company's Capital are performed via the Own Risk and Solvency Assessment ("ORSA") process (see Section B.3.3 below), and the capital position is stressed to test for the Company's resilience to unexpected events. Stress testing is also completed on the annual business plan.

Through the RMS's various reporting mechanisms the Board is kept informed, and the strategy is reviewed at least annually considering the Company's risk profile.

An overview of the key aspects of the Company's risk management process is as follows:

B.3.2.1 Top-down risk assessment

Senior Management with the guidance and advice of the CRO perform a 'top-down' risk assessment to identify and monitor the key risks that may threaten the achievement of the Company's goals. This is a regular and continuous process and reported quarterly to the Board.



B.3.2.2 Emerging risks monitoring

Emerging Risks are new and unforeseen risks, or re-emerging risks whose potential for impact on the Company's strategic objectives are uncertain due to insufficient information or time to fully analyze the emerging impact. The RMF in conjunction with the front line performs horizon scanning and engagement with internal and external stakeholders to identify new or changes to risks. These are then evaluated, prioritized and management actions agreed. Once an emerging risk becomes a live risk, it is transferred to the Top Risks or RCSA, if an emerging risk does not materialize, it is retired. Quarterly updates on emerging risks are provided to the Risk and Compliance Committee.

B.3.2.3 Risk Appetite and Key Risk Indicator (KRI) The Company Risk appetite sets out the amount of risk the Company is willing to take in pursuit of its strategic objectives. It considers the risk profile of the Company and what the top risks to achieving our objectives. A Company risk appetite statement is in place which articulates the appetites for each risk, including the quantitative and qualitative limits and tolerances in place. The statement also includes a number of key risk indicators which are also in place to support the risk appetite. Thes are monitored and reported to the Risk and Compliance Committee and the Board on a quarterly basis.

B.3.2.4 Risk and Control Self-assessments (RCSAs)

The Company has a Risk and Control Self-Assessment (RCSA) Framework to identify, assesses and monitors the potential risks in our operations.

RCSA risk registers, are in place for on a functional basis companywide and overseen by the RMF. Risks and controls are recorded in the risk registers. All risks are evaluated and given an inherent, residual and target rating, using the risk matrix. RCSAs are reviewed on an annual basis in conjunction with quarterly "check-ins" or following changes to the business. The RCSA's continue to be reviewed as they embed into the business.

In addition to this process, all employees are encouraged to report any additional risks, errors or near misses to the RMF as soon as possible after it is identified. See risk incidents section below.

B.3.2.5 Risk Incident reporting and escalation

The Company operates a risk incident reporting and escalation framework designed to capture the occurrence of operational risk events for the purpose of analysis, reporting and improvement of internal controls.

All staff are responsible for identifying and reporting risk incidents. Once identified, incidents are reported to the RMF. Incidents are recorded and tracked in a dedicated repository. Incidents are reviewed by the Risk function and an action plan put in place to identify the root cause and remediate. Incidents are reported and escalated to the appropriate level, depending on their severity.

B.3.2.6 Stress testing

Stress tests are applied to the Company's business plan at least annually as part of the ORSA process, business planning process, recovery planning and by the Exposure Management team. A range of scenarios is considered, based on the key risks to strategic objectives. The results of the scenarios are then considered to inform management decision making. The scenarios which produce the biggest losses are further stressed to produce Reverse Stress Tests to determine the point at which the Company would fail.

Stress tests are performed periodically or ad hoc, as needed or whenever there is a material change in risk profile, which would include but is not limited to; material change to reinsurance agreements, entry into a new class of business, change in investment policy or purchase of a subsidiary by the Company.

B.3.2.7 Stochastic Modelling

The Company has developed a stochastic model which will be used to evaluate its Insurance Risk exposure, e.g., scenario analysis or consideration of appropriate solvency risk appetite limits. Capital requirement calculations and assessment of capital needs in the ORSA are based on the standard formula.

B.3.2.8 Capital allocation

The Company currently allocates capital to classes of business at a high level. Capital needs are assessed as part of the ORSA process and the solvency forecasting activities. With the development of a stochastic capital model, the capital allocation process will be further strengthened.

B.3.2.9 Recovery and Resolution Plan

The Company is required to maintain recovery and resolution plan. The plan is reviewed annually and if necessary, updated.

The recovery plan aims to prevent the business from failing while it is a going concern and includes measures to restore our financial position in the event of financial deterioration and includes realistic assumptions for various severe scenarios and how we would identify and address them.

The recovery plan includes a framework of indicators that identify, in a timely manner, progression of risks that have the potential to threaten our financial viability. In the event that these indicators give rise to concern, they are either: escalated in accordance with our governance requirements, monitoring increased or the implementation of one or more recovery options.

The resolution plan aims to ensure orderly failure of a business and includes: identification of critical economic functions; key dependencies between entities and functions; and preferred resolution strategies and their implications.

B.3.2.10 Climate Change Risk Management

The Company has a Climate Change Financial Risk Management Framework in place to provide a coherent approach to assess what the Company needs to put in place to manage the financial risks relating to climate change. The framework sets out the process to identify, measure, manage, monitor and report upon the financial impact to the Company which may result from this phenomenon. We continue to monitor climate change and sustainability developments and will update and adapt our approach as required.

B.3.3 Own Risk and Solvency Assessment (ORSA)

The Own Risk and Solvency Assessment brings together the ERM processes described above, enabling the Board to assess, monitor, manage, and report the short- and long-term risks that the Company faces or may face and to determine the Own Funds necessary to ensure that the Company's overall solvency needs are always met.



The ORSA process is strongly linked to the Board's approval of the Company's strategy and business plans, which ensures that the ORSA is embedded in strategy and decision-making. Risks identified through the RCSA process, and the top-down risk assessment form the basis of stress test scenarios, which are selected and approved by the Board. This allows the Company to test risks to its strategy.

The Company completes its full ORSA process on an annual basis and whenever there is a material change in its risk profile. Changes in risk profile are monitored through the quarterly Board reporting process.

The Company determines its overall solvency needs by determining its projected regulatory capital requirements given the Board approved business plan The Company has set a solvency risk appetite which has been determined with reference to a stress event. This includes appropriate corridors for varying levels of action in the case of a deterioration in solvency coverage.

This combined with stress and scenario testing gives the Board comfort that the Company has sufficient capital resources to fulfil its strategy.

B.4 Internal control system

B.4.1 Internal Control system

Internal control is integral to risk management and the principal means by which risk is managed and ensures compliance with all applicable laws, regulations and administrative provisions

A Group internal control policy is maintained and adopted by the company

Due to the nature of our business and the materiality of our outsourcing arrangements there are internal control systems in place and oversight is in place with regard to the aspects of the internal control systems within the service provider.

Primary responsibility for the identification, monitoring, control and reporting of significant risk rests with the heads of the various business functions on an on-going basis. Risk and control owners are identified for all significant risks and controls. The Enterprise Risk Management framework ensures that these risks and controls are reviewed on a regular basis.

The system of internal control constitutes the first and second Lines of Defence of the "Three Lines of Defence" risk management model (referred to above).

The Internal Audit function is responsible for auditing the control environment against the audit plan agreed by the Audit Committee.

On behalf of the Board, the Audit Committee and the Risk and Compliance Committee regularly review the Company's system of internal control. The review covers all controls, including financial, operational and compliance controls, completeness and accuracy of data and the risk management process. Necessary actions are taken to remedy any significant control failings or weaknesses identified.

Prior to AFSI becoming a private company, by virtue of being a material overseas subsidiary of AFSI, the Company was subject to the legal requirements of the US Sarbanes-Oxley Act, Section 404 ('SOX'). This Act requires the external auditor of AFSI and its management to report on the effectiveness of the Company's internal controls under the Public Company Accounting Reform and Investor Protection Act 2002. A central SOX controls framework was developed at AFSI Group level, which is cascaded down to

all material subsidiaries within the AmTrust group. AFSI and accordingly, the Company is no longer obliged to comply with SOX. Nevertheless, the Company continues to adopt the SOX approach and the key SOX controls within the Company's framework are routinely tested and attested by management. Management produces an internal control report which assesses the effectiveness of the internal control structures and processes around financial reporting. The assessment is risk-focused and includes:

- Assessment of the design and operating effectiveness of internal controls around significant accounts (i.e. where there is a risk of material misstatement) and relevant assertions.
- Understanding of the flow of transactions to identify points where a misstatement could arise.
- Assessment of entity-level controls.
- Fraud risk assessment.
- Evaluation of controls in place to mitigate the risk of fraud.
- Assessment of controls in place over the financial reporting process.
- Scales the assessment based on the size and complexity of the Company; and
- Conclusion on the adequacy of internal control over financial reporting.

Compliance with these controls under this process is monitored by the Internal Audit function. The outcomes of monitoring are reported to senior management and any control deficiencies identified at the Company are reported to management for consideration of the aggregate impact to the control framework of the AFSI group.

B.4.2 Compliance function

As part of its system of internal control, the Company has in place a Compliance function which is established as an independent second line control function and has a formal status within the Company's governance arrangements.

The Compliance function reports to the Head of Compliance and is responsible for advising the Executive and the Board on the Company's compliance with existing and emerging legal, regulatory and administrative provisions.

Compliance has ultimate recourse to the Company's Board and has the right to escalate to the Board, directly or through its committees, any instances of non-compliance.

The Compliance function has responsibility for identifying and assessing the wide-ranging internal and external regulatory obligations that the Company has and for promoting an organisational culture that encourages ethical behaviour and helping ensure that the Company clearly understands its regulatory risks and the prevailing requirements. The Compliance function is responsible for setting policies that the business must work within to control compliance risk, such policies being in accordance with consistent group standards where applicable.

The function monitors that compliance obligations are being met after management implementation providing the Company with a systematic, disciplined and risk-based approach to evaluating the effectiveness of its compliance controls.



B.5 Internal audit function

Internal Audit is established by the Audit Committee of the Board of Directors of the Company ("Audit Committee") to assist the Board and Executive Management to protect the assets, reputation and sustainability of the organisation. While Internal Audit does not provide absolute assurance around all risks and controls, Internal Audit strives to provide senior management and the Audit Committee with information, analysis and recommendations about the adequacy, effectiveness and efficiency of the business operations and internal control environment.

This is achieved by:

- Assessing whether all significant risks are identified and appropriately reported by management and the Risk function to the Board and Executive Management.
- Assessing whether they are adequately controlled; and
- By challenging the management team to improve the effectiveness of governance, risk management and internal controls.

Internal Audit is independent from the business and is directly responsible to the Chair of the Audit Committee, with a day-to-day administrative reporting line to the AmTrust Group Chief Audit Officer. Internal Audit has free and unrestricted access to the Chair of the Board, the Chair of the Audit Committee and the Chief Executive Officer.

Those working within Internal Audit are not permitted to perform day-to-day control procedures or take operational responsibility for any part of AmTrust's operations outside Internal Audit. Management is responsible for the establishment and ongoing operation of the internal control system. The Audit Committee reviews the scope and nature of the work performed by Internal Audit to confirm its independence.

Internal Audit will comply with Am Trust's Code of Conduct and the updated International Professional Practices Framework (IPPF) that include Global Internal Audit Standards of the Institute of Internal Auditors and the Guidance on Effective Internal Audit in the Financial Services Sector of the Chartered Institute of Internal Auditors.

Internal Audit complies with Am Trust's Code of Conduct and the updated International Professional Practices Framework (IPPF) that include Global Internal Audit International Standards for the Professional Practice of Internal Auditing of the Institute of Internal Auditors and the Guidance on Effective Internal Audit in the Financial Services Sector of the Chartered Institute of Internal Auditors.

B.5.1 Internal Audit Policy

Internal Audit operates under an Internal Audit Charter which is reviewed and approved by the Audit Committee on an annual basis. The Global Audit Methodology and Sarbanes Oxley Methodology for Internal Audit have been updated annually and are being applied consistently across the global function. There were no significant changes to the policy during the period.

B.5.2 Internal Audit Plan

The Internal Audit function produces an annual Internal Audit Plan, which is discussed and approved by the Audit Committee on an annual basis. This Internal Audit Plan is specific to the Company and



remains flexible for future developments to the risk horizon of the entity. The plan and the way it is executed is performed using a consistent risk-based approach.

Progress against the Internal Audit Plan is reported to the Audit Committee on at least a quarterly basis.

B.5.3 Independence of the Internal Audit Function

The Internal Audit Function has been and remains independent from other functions within the Company. The Head of Internal Audit for AmTrust International has not assumed any responsibility for any other function.

B.6 Actuarial function

The purpose of the Head of Actuarial function ("HoAF") and Actuarial function within the Company is to provide support to the Company in many areas including reserving, pricing and capital management. Additionally, other statistical and management information support is provided where necessary. This work is required to be undertaken in an objective and independent manner whilst incorporating feedback from the business where appropriate.

Under Solvency II the Actuarial function is a Key Function, the HoAF being the Key Function holder. The HoAF is a qualified actuary and is a Fellow of the Society of Actuaries in Ireland. Other members of the team are either qualified actuaries; working towards becoming a qualified actuary; or sufficiently qualified by experience to undertake the duties assigned to the individual.

The HoAF or his representative attends (and is a member of) the Reserving Committee and the Investment and Capital Management Committee. The HoAF also attends and presents to the Audit Committee. The HoAF will rely on work produced by other members of the Actuarial function to fulfil the necessary roles and responsibilities.

The Actuarial function has the following specific responsibilities:

- Preparation of an Actuarial function report annually to the Board which reports on the activities of the Actuarial function and which supports the required opinions from the HoAF.
- Production of the Technical Provisions in accordance with Solvency II principles and ensuring
 that methodologies and underlying models used are appropriate for the specific lines of
 business of the undertaking and for the way the business in managed, having regard to the
 available data.
- Assessment of whether the information technology systems used in the calculation of technical provisions sufficiently support the actuarial and statistical procedures.
- Preparation of the Actuarial Report on Technical Provisions.
- Monitoring the best estimates against actual experience.
- Reporting to the Board on the reliability and adequacy of the Technical Provisions calculation.
- Providing a statistical framework to price various lines of business.
- Reviewing new business opportunities and providing feedback on the underlying models and assumptions or any external actuarial models used.
- Work with underwriters to provide support on product performance.
- Providing independent input into the ULRs to be used in the Business Plan.
- Providing inputs into the calculation of the Solvency Capital Requirement ("SCR").

- Assisting with the preparation of business plans.
- Working closely with the Risk Management Function ("RMF") to facilitate the implementation of an effective risk management system.
- Support to the Risk Management Function to quantify the risks identified.
- Modelling the Insurance risk faced by the Company; and
- Opining on the Technical Provisions, the Underwriting Policy, Reinsurance arrangements and the ORSA process.

B.7 Outsourcing

Outsourcing is an important aspect of the Company's business model and supports its business strategy by leveraging enterprise infrastructure and resources, to

- avail of shared operations, products and related investment,
- advance innovation, achieve efficiencies of scale and provide a robust service for its customers; and
- leverage the expertise of specialist third parties.

Outsourcing risk refers to those functions that are required by the Company; either from external or from intra-group providers which are essential to the Company's operations, and that the Company would, otherwise, be unable to deliver its services to policyholders without the outsourced function(s).

The Company's key outsourcing risk lies in its use of third-party administrators, coverholders, agents and intermediaries in its claims and complaints handling, underwriting and distribution processes. Furthermore, the Company has intra-group outsourcing arrangements in place, providing services across HR, Finance, IT, Claims, Internal Audit, Actuarial, Legal, Investment Management and Underwriting.

The CBI requires the Company to take reasonable steps to avoid undue additional operational risk and not to undertake the outsourcing of key functions in such a way as to either: impair the Company's internal controls; or risks associated with the CBI's ability in monitoring the Company's compliance obligations under the regulatory system.

The Company has undertaken an Operational Resilience program to strengthen the Company's ability to deliver critical and important business services in case of a disruptive event with no material impact to customer outcomes and the Company's soundness and viability. The Company performs scenario testing to ensure that the control framework is sufficiently robust to withstand plausible but extreme events, delivering critical and important business services within agreed impact tolerances. Critical and important business services performance against agreed impact tolerances is also monitored regularly. In 2024, the company self-assessed its Operational Resilience program and worked on embedding it in business-as-usual activities. The Company's Outsourcing Committee provides governance, oversight and recommendations to the Executive Management Team on matters relating to all outsourcing arrangements with third party and intra-group outsourcing service providers. The Delegated Oversight Committee is also responsible for monitoring and reviewing the effectiveness of the internal controls required to manage outsourcing risk.





The Company's Outsourcing internal control framework, includes but is not limited to:

- Due diligence undertaken of a prospective provider in order to identify the potential operational, prudential and conduct of business regulatory risks that may be associated with the placement of the outsourced function to the specific provider(s).
- Enhanced due diligence performed on all critical and important service providers.
- Formal contract management and monitoring.
- Contingency plans in the event that the service providers are unable to perform the service.
- Independent internal monitoring by business operations, the control functions of risk, compliance and internal audit; and the Company's third-party audit coverage as routinely approved and monitored by the Executive Management Team.

The Company has designated the following outsourced functions, overleaf, as critical or important for both intra-group and external third-party service providers:

Outsourcing to Amtrust Group	
Activity or function that is outsourced Operations, Claims admin services, IT, Internal Audit, Finance, , DPO,	Location of Service Provider
Facilities & Real Estate, Actuarial and HR	Ireland & UK
Claims handling services	USA
Investment management services	USA
Operational support, claims handling, distribution and complaints	
services	Sweden
Premium administration	Sweden

Outsourcing to External Service Provider	
Activity or function that is outsourced	Location of Service Provider
Coverholder	*EEA
Coverholder	USA
Premium administration, claims services and complaints services	*EEA
Premium administration, claims services and complaints services	USA
* List of EEA Countries where partners are located	Denmark, Sweden, France

B.8 Any other information

None noted.

Risk Profile

Section C

C. Risk Profile

This section outlines the main risks the Company faces. These include risks which are captured under the Standard Formula in the calculation of the SCR and those material risks not covered explicitly under the Standard Formula.

The Company calculates its regulatory capital using the Standard Formula. A breakdown of the SCR result of €129.2k at December 31, 2024 is provided in Section E.2.1. The Own Funds available to meet the SCR at December 31, 2024 were €215.9m and the solvency ratio was 167.1%. Therefore, the Company had excess Own Funds of €86.7m, over the SCR.

C.1 Underwriting risk

Underwriting risk refers to fluctuations in the timing, frequency and severity of insured events, relative to the expectations of the firm at the time of underwriting.

The Company uses a suite of risk appetite and key risk indicator metrics to monitor its exposure to underwriting risk that are evaluated each quarter. These include volume of premium underwritten, by class of business; priced loss ratios in comparison with plan; ultimate loss ratios in comparison with plan; concentration of premium and profit contribution by class and deterioration in prior year reserves.

C.1.1 Material risk exposures

The Company is exposed to premium risk, that is, the risk that premiums are insufficient to cover the value of claims made and reserve risk, the risk that on-going claims are settled at a higher value than previously expected. The largest class of business, based on GWP, during 2024 was Miscellaneous Financial Loss. In addition, other material lines of business in terms of size are Credit & Suretyship and General Liability. Casualty insurance and underlying claims exposures can take a long time to properly realise, hence there is a material risk of adverse reserve development on all current and prior underwriting years where the Company underwrote these types of programmes. The SCR quantifies the potential for adverse development as part of the calculation of the premium risk and reserve risk calculation.

C.1.2 Material risk concentrations

The Company's underwriting risk exposure is concentrated in the Miscellaneous Financial Loss and Credit & Suretyship classes of business. Approximately 83% of the Company's premium for the year is attributable to these classes, however it should be noted that these are diversified across a range of territories and products.

C.1.3 Material risk mitigation

This risk is mitigated through a range of management controls including the Risk Authority Form ("RAF") process, which is a key control. In addition to the RAF process, the Actuarial Pricing team review new business to determine that rates are adequate. Within underwriting teams, a peer review also takes place. There is constant monitoring of underwriting performance by management, which allows corrective action to be taken if a piece of business is not performing as expected. Furthermore, underwriting performance is monitored against risk appetites in terms of volume of written premium, underwriting profit and concentration via the KRI reporting process.



The Company also uses reinsurance to mitigate underwriting risk. The comprehensive reinsurance programme is made up of quota share treaties, excess of loss treaties, a small number of facultative placements and a loss prevention reinsurance treaty ("LPT") with AIIL. The LPT transaction provides the Company with economic certainty and protects its capital base from any exposure to reserve deterioration. All material reinsurance arrangements must be approved by the Board.

The main external quota share treaty is with Swiss Re to which the Company cedes 50% of business covering most lines of business. This Swiss Re arrangement has been in place since July 2019. There are also internal quota share treaties – there are historical intra-group quota share treaties and live quota share treaties ceding 100% of the Company's two US lines of business to AIIL and TIC. During 2022 the LPT was executed with AIIL via a 100% quota share reinsurance arrangement in respect of specific historic business on a rolling basis for each underwriting year. This was renewed in June 2024 to include the 2021 underwriting year.

The reinsurance strategy is reviewed by management on a regular basis to ensure it remains effective and appropriate and is approved by the Board at least annually.

C.1.4 Risk sensitivities

The Company has performed a series of sensitivity tests on its solvency position; these are shown in section C.7.

C.1.5 Other material information

None noted.

C.2 Market Risk

Market risk is the risk of loss of income or decrease in the value of assets caused by movements in the level and prices of financial instruments. Market risk includes factors such as equity values, property values, interest rates, foreign exchange and spread risk.

The Risk Appetite Statement process identifies and measures the key market risk exposures by closely monitoring the currency and duration mismatch to capture exposure to currency and interest rate risks, as well as the composition of the bond portfolio holdings by credit ratings to capture exposure to spread risk.

Investments are reviewed quarterly via the Investment and Capital Management Committee; investments are also reviewed on a quarterly basis by the Board.

C.2.1 Material risk exposures

The Company's material exposures to market risk relate to spread risk on its bond portfolio and foreign exchange risk on its currency exposures.

The bond portfolio consists mainly of corporate and government bonds. It is exposed to interest rate risk as well as to credit-spread risk. Fluctuations in rates of inflation influence interest rates, which in turn impact the market value of the investment portfolio and yields on new investments. Thus, rising interest rates would likely have an adverse impact on the bond portfolio and would drive the value of the bonds down. Whereas, widening credit-spreads would also negatively impact the value of the bond portfolio.

The Company does not hold any properties as investments at 31 December 2024, but does own its branch office in Italy. This does not however pose any material market risk to the Company's business.

The Company manages its foreign exchange risk against its functional currency, which is Euro. Foreign exchange arises when future commercial transactions or recognised assets and liabilities are denominated in a currency that is not the entity's functional currency. The Company is exposed to currency risk in respect of liabilities under policies of insurance denominated in currencies other than Euro. The most significant currency to which the Company is exposed is the US Dollar.

C.2.2 Material risk concentrations

The Company's material market risk exposures are to its foreign currency exposure to the US Dollar, Danish Kroner, Norwegian Kroner and Swedish Kroner and the exposure of its predominantly fixed rate corporate bond investment portfolio to spread risk.

C.2.3 Material risk mitigation

The Company operates a conservative investment strategy, investing primarily in fixed rate corporate bonds, sovereign bonds, money market deposits and cash. The Company has little appetite for investments in equities (other than wholly owned subsidiaries) and complex investments such as derivatives. By investing in assets where the risk can be properly identified, measured, monitored, managed, controlled and reported on, the Company fulfils the Prudent Person Principle.

Investment management is outsourced to another group company (as part of a shared services model). A set of investment management guidelines has been drawn up, adherence to which is monitored by the Investment and Capital Management Committee, Risk and Compliance Committee and the Board.

The Company monitors interest rate risk as part of its regulatory reporting process by monitoring duration of assets and liabilities. Any gap between the mean duration of the assets and the estimated mean duration of the liabilities is discussed at the ICMC and, where required, this gap is minimised by means of buying and selling fixed interest securities of different durations.

The Company is exposed to foreign exchange risk, by operating in multiple currencies. The Company seeks to mitigate the currency risk by matching the estimated foreign currency denominated liabilities with assets denominated in the same currency.

C.2.4 Material risk sensitivities

The Company has performed a series of sensitivity tests on its solvency position; these are shown in section C.7.

C.2.5 Other material information

None noted.

C.3 Credit risk

Credit risk is the potential loss arising principally from adverse changes in the financial condition of the intermediaries which sell the Company's products, issuers of fixed maturity securities and the financial condition of third-party reinsurers.

Management identifies and measures key credit risk exposures by monitoring the ratings of banks, ratings of reinsurers, bond ratings, exposure to individual external/internal reinsurer counterparties,

Solvency and Financial Condition Report

exposure to a single bank as a percentage of the SCR, credit extended to intermediaries and length of time overdue.

C.3.1 Material risk exposures

The Company is subject to material risk exposures with respect to its reinsurers, intermediaries, banks and bond counterparties.

C.3.2 Material risk concentrations

The Company is exposed to credit risk in relation to material accounts with reinsurance and premium counterparties.

The Company is exposed to general economic, business and industry conditions. Adverse general economic conditions may cause, among other things, significant reductions in available capital and liquidity from banks and other credit providers. The Company's largest bank exposures are to Intesa San Paolo and JP Morgan Chase.

C.3.3 Material risk mitigation

In order to reduce exposure to reinsurance credit risk, the financial condition of reinsurers is evaluated, and reinsurance is placed with a diverse group of companies and syndicates that are believed to be financially sound. The large exposure to the AIIL quota share is collateralised in line with reinsurance agreements and the LPT reinsurance arrangement with AIIL is on a funds withheld basis as at December 2024. The Swiss Re quota share contract that renewed on 1 July 2024 is on a reserves withheld basis, reducing the net exposure. The credit quality of reinsurers is monitored when placing new and renewal reinsurance, as well as on an ongoing basis. The Company uses objective criteria to select and retain its reinsurers, including requiring a financial strength rating of "A-" or better from A.M. Best Company and/or Standard & Poor's rating of "A-". Where a reinsurer does not hold such a minimum security rating, appropriate governance is in place to review such counterparties. Ongoing adherence to this is reported to the Board through risk appetite monitoring.

To reduce credit risk, the Company performs ongoing evaluations of its intermediaries' financial condition.

Credit risk related to the issuers of fixed maturity securities is addressed by investing primarily in fixed maturity securities that are rated "BBB-" or higher by Standard & Poor's. Exposure is limited by the employment of diversification policies that limit the credit exposure to any single issuer or rating.

The Company manages the levels of credit risk it accepts by reviewing exposures regularly and reporting to management of significant counterparties. Credit limits are also in place for certain counterparties as is deemed appropriate within the business.

Exposures to individual policyholders and groups of policyholders are considered through the ongoing monitoring of the controls associated with regulatory solvency.

Exposures to banks are limited to those whose credit ratings are A or higher, except where required for business reasons, typically in jurisdictions where there are no A rated banks available. In this case, exposures are kept to a minimum.



C.3.4 Risk sensitivities

The Company has performed a series of sensitivity tests on its solvency position; these are shown in section C.7.

C.3.5 Other material information

None noted.

C.4 Liquidity risk

Liquidity risk represents the Company's potential inability to meet all payment obligations when they become due and the risk stemming from the lack of marketability of an investment security that cannot be bought or sold quickly enough to realise cash.

The Finance team and the Shared Services Treasury team, carries out regular cash-flow forecasting and analysis to monitor the Company's liquidity needs.

C.4.1 Material risk exposures

There are no material risk exposures to liquidity risk, as most assets are invested in highly liquid government and corporate bonds. Risk appetite limits are in place to monitor the liquidity of our investment portfolio.

However, the major threat to liquidity could occur during a catastrophe when a large number of claims are received at once or there may be a prospect of a major significantly large claim. The Company considers this scenario to be remote.

Reinsurance may additionally pose a residual liquidity risk through delays in payment by the reinsurer or its default which, while classed as a credit risk event would also present a potential liquidity issue.

C.4.2 Material risk concentrations

The Company's liquidity risk exposure is concentrated in reinsurance contracts and financial assets (bonds).

C.4.3 Material risk mitigation

The Company's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise the potential adverse effect on the Company's financial performance. It manages these positions within an asset liability management (ALM) framework that has been developed to minimise the risk of significant deterioration of the investment portfolio while earning profitable returns from those investments.

The Company invests mainly in corporate and sovereign bonds, which are normally readily convertible into cash, so it holds relatively small amounts of cash. It accepts the risk that during times of stress, there may be market value losses realised by liquidating bonds.

The Company maintains sufficient cash and highly rated marketable securities, to fund claim payments and operations.



C.4.4 Expected profit in future premiums

The value of expected profit in future gross premiums is €34.4m. This amount is highly illiquid but represents only 16% of the value of own funds. This is an increase compared to 2023 when the figure was €6.7m net of reinsurance. Current year EPIFP is on a gross of reinsurance basis excluding loss making reserving classes. Reserving class has been implemented as the basis for the Homogeneous risk groups this year compared to S2 LOB last year.

C.4.5 Risk sensitivities

Unless there is a larger claim payment due to a major catastrophe event or a default in collecting reinsurance receivables due to adverse market conditions, the Company has no significant sensitivity to liquidity exposures.

C.4.6 Other material information

None noted.

C.5 Operational risk

Operational risk is the risk that the Company will not be able to operate in a fashion whereby the strategic objectives of the Company can be met due to inadequate or failed internal processes, people and systems, it arises out of actions undertaken within the Company, intermediaries, investment management companies or outsourced agencies and individuals.

The Company has risk management processes in place, such as third-party audit, internal audit, controls testing, project management, risk and control self-assessment (RCSA), an internal control system and management governance committees to assess and monitor operational risk exposures.

C.5.1 Material risk exposures

The Company is exposed to Operational Risk across aspects of our business and can be broken down further into business continuity risk, business process risk, compliance risk, distribution risk, human resource risk, outsourcing and third party risk, information systems risk and fraud risk. As a result of limitations inherent in all control systems, it may not be possible to prevent all fraud or errors from occurring, however the control environment has been designed with the intent of being able to prevent or detect material incidents. Judgements in decision making can be faulty and breakdowns may occur through simple human error.

In addition, any ineffectiveness in internal controls could have a material adverse effect on the Company's business. For instance, failure to maintain proper oversight of our outsourced providers, pricing disciplines and robust underwriting controls; poor quality management information or IT systems to capture data and business performance; failure to appropriately account for reserves, f; a potential reduction of control over the actions of third parties operating on its behalf (outsourcing).

The Insurance platform project planned for 2025 exposes the Company to heightened level of inherent operational risk due to the introduction and transition to a new system, and the resulting changes to impacted processes. Management are monitoring this closely to ensure the risks are appropriately managed.





C.5.2 Material risk concentrations

The Company's material risk concentrations are in Systems and Outsourcing.

The majority of the Company's core lines are sold through independent third-party intermediaries, agents, retailers or administrators, (TPA's), many of whom the Company has worked with for several years, in particular in the Casualty and Warranty accounts.

Information Technology ("IT") is an integral aspect of the Company's day-to-day business operations and as such, any system failure can impose a serious threat to the Company operations. IT is a global function, aspects of which are managed and maintained centrally via teams in the US and UK. IT has many components including Infrastructure Operations and Engineering; Security; Data Governance; System Development; Governance and Operations.

C.5.3 Material risk mitigation

The Company does not seek to take on operational risk to generate a return. However, it recognises that some degree of operational risk is an unavoidable consequence of remaining in business. It therefore seeks to mitigate this risk through its corporate governance framework, operational risk management framework and internal control system. An IT Risk Management Framework is now in place with regard to IT Risks and a robust governance program is in place to monitor the outsourcing providers.. All the Company's operational risks are captured within the Company's operational risk registers (RCSA's). Quarterly check in's are in place with Management to validate the RCSA's and they are reviewed at least annually.

C.5.4 Risk sensitivities

The Company has performed a series of sensitivity tests on its solvency position; these are shown in section C.7.

C.5.5 Other material information

None noted.

C.6 Other material risks

C.6.1 Legal and Regulatory risks

The risk of non-compliance with regulation and legislation.

The Company does not seek to take on legal and regulatory risk to generate a return. However, it recognises that some degree of legal and regulatory risk is an unavoidable consequence of remaining in business. It therefore seeks to mitigate this risk through its corporate governance framework and internal control system. Awareness of the risks and the Company's control mechanisms are maintained through its policies and procedures framework and training programmes.

C.6.2 Strategic risk

Risks arising from failure to sufficiently define the direction and objectives of the entity, together with the resourcing and monitoring of the achievement of the same.

The Company has a well-developed business planning process and its business plans are approved by the Board. The business planning and ORSA processes are also aligned.

A key source of strategic risk for the Company across 2024 and 2025 is the new insurance platform project. Robust project governance is in place and progress is monitored closely by Management and the Board.

C.6.3 Governance risk

Risks arising from the failure to demonstrate independent and proper stewardship of the affairs of the entity to safeguard the assets of the entity's shareholders and the overall interests of its stakeholders.

The Company regards a strong Governance framework to be vital in achieving its objectives as well as providing transparency and accountability to its various stakeholders. A system of internal control and governance has been developed using the "three lines of defence" model.

C.6.4 Group risk

The risks arising from other parts of its group, through parental influence or direct contagion.

The Company maintains a good relationship with its ultimate parent and expects that, at all times, it will remain suitably apprised of all the material risks within the group that may, if crystalised, have a negative impact upon the business strategy and/or cause detriment to its customers.

There is regular engagement between executives and senior managers of AFSI and the Company. The Company's Board composition includes two Group Non-Executive directors.

C.6.5 Solvency risk

The risk that the entity fails to maintain adequate levels of capital resources of sufficient quality and quantity to carry out its business objectives and to meet all domestic and international regulatory considerations regarding the capital resource requirements.

The Company ensures it is always solvent through: monitoring of its solvency position; management accounts; solvency forecasting in ORSA prior to any strategic decision making.

C.6.6 Reputational risk

The risk relates to potential losses resulting from damage to the Company's reputation, which could be manifested in terms of lost revenue; increased operating, capital or regulatory costs; or destruction of shareholder value.

The Company manages reputational risk by operating to high standards across its business activities, and continuously monitoring feedback from its key stakeholders, including customers and regulators.



C.7 Any other information

The Company has performed sensitivity tests to show the impact on SCR and solvency coverage by changing the assumptions associated with each risk type in the SCR calculation. These are independent stresses to individual risks, although in practice risks may occur in combination, but the impact would differ from the combination of impacts of the individual stresses. The sensitivity tests have been prepared without consideration of any Management actions to give the indication of the possible impact. In the event that any of these developed Management would consider an appropriate response. The impacts of each stress are non-linear and the results shown should not be used to extrapolate the effects of larger or smaller changes in the assumptions.

The Company has performed the following sensitivity tests on its solvency position.

	SCR/Change		Own Fund	ls/Change	Solvency Rati	o/Change
Base	129.2	-	215.9	-	167.1%	-
Large Claim Event	131.3	2.1	205.4	-10.4	156.5%	-10.6%
TP Assumption Change	129.3	0.1	212.7	-3.1	164.6%	-2.5%
Currency Increase	130.5	1.3	215.9	-0.0	165.4%	-1.7%
Currency Shock	130.5	1.4	220.0	4.2	168.6%	1.5%
Concentration Increase	129.2	-0.0	215.9	-0.0	167.1%	0.0%
Type 2 Increase	130.2	1.0	215.7	-0.1	165.7%	-1.4%
Duration Increase	129.9	0.7	215.9	-0.0	166.2%	-0.9%
Duration Decrease	128.8	-0.4	215.9	-0.0	167.6%	0.6%
Property Shock	129.1	-0.1	214.3	-1.6	166.0%	-1.1%
Reinsurer Balance & Investments	129.2	0.0	215.8	-0.0	167.1%	-0.0%
Yield Curve Upshock	127.7	-1.5	214.0	-1.8	167.6%	0.5%
Yield Curve Downshock	130.6	1.4	217.8	1.9	166.7%	-0.4%
Reinsurer Downgrade	130.4	1.2	215.7	-0.1	165.5%	-1.6%
Reinsurance exposure deterioration	130.6	1.5	215.7	-0.2	165.1%	-2.0%

	Notes
Base	Q4 2024
Large Claim Event	This scenario models an increase in gross claims provisions of €20m and an increase in net claims provisions of €10m with the other €10m being ceded to Swiss Re. NL and Health risk go up from increase in CPs, market risk decreases from upshock TPs increasing by less than the base TPs.
TP Assumption Change	This scenario models a €3.0m gross increase in the unearned operating expenses. These are not ceded so results in a €3.0m increase in the TPs. Small increase in operational risk and €3.1m decrease in own funds because of €3.0m increase in net TPs plus €0.6m increase in risk margin, less deferred tax impact €0.5m.
Currency Increase	This scenario models a 25% increase in USD net assets without an increase in own funds. Implicitly assuming an offsetting decrease in the EUR net assets. The only change made is on currency risk, no changes have been made to other market risks. As expected, holding a higher proportion of foreign assets increases currency risk.
Currency Shock	This scenario models a 10% appreciation of USD compared to EUR. This results in the value of USD assets and liabilities increasing by 10%. Net USD assets are greater than zero so own funds increases, along with an increase to market risk in the SCR.
Concentration Increase	This scenario models a doubling of the two largest investments (both of which are government bonds and don't contribute to concentration risk), offset by a pro rata decrease in the others. These changes are only being made to concentration risk, no changes made to other market risks. Concentration risk doubles but total market risk increases by less than 1%.
Type 2 Increase	This scenario models a 10% increase in both Type 2 exposures, which is offset by a decrease in investments of the same value. The increase to counterparty default risk is partially offset by the reduction in market risk. Increase in Type 2 debt increases risk margin.
Duration Increase	This scenario models a 0.5 year increase to the durations of the assets held. Results in an increase to interest rate risk and spread risk.
Duration Decrease	This scenario models a 0.5 year decrease to the durations of the assets held (but all durations kept greater than or equal to 0). Results in an decrease to interest rate risk and spread risk.
Property Shock	This scenario models a 10% decrease in property value, decreasing own funds and causing small reduction to Property risk.
Reinsurer Balance & Investments	This scenario models a 10% decrease in RI balances (assigned wholly to Swiss Re) and an offsetting increase in investments. SCR increases marginally as the increase in market risk is higher than the reduction in counterparty risk.
Yield Curve Upshock	This scenario models a yield curve upshock (using shocked rates from EIOPA), causing a reduction in currency risk. The €6.2m reduction in bonds is partially offset by a €4.1m reduction in net TPs and increase in deferred tax asset of €0.2m.
Yield Curve Downshock	This scenario models a yield curve downshock (using shocked rates from EIOPA), causing a increase in currency risk. The €6.0m increase in bonds is partially offset by a €3.8m increase in net TPs and decrease in deferred tax asset €0.3m.
Reinsurer Downgrade	This scenario models the downgrade of the largest external reinsurer by one credit quality step (Everest Re Group Ltd from 2 to 3). Type 1 default risk increases by 22%. RIBD assumptions in the TPs remain unchanged.



Reinsurance exposure deterioration

This scenario models an increase in gross claims provisions of €50.0m but no increase in net claims provisions (so no change in own funds), with the whole €50.0m being ceded to AII. Operational risk increases by 3% of €50.0m, Type 1 risk decreases slightly because of decrease in RM effect of non-AII reinsurers.

The tests highlight a material sensitivity in terms of solvency ratio to a large claim event. Claim reserve movements are monitored via detailed reporting to the Reserving Committee and the Claims Committee. The Company has robust controls in place to ensure the reserves are appropriate, as set out in section B.1.1.7. The Actuarial function provides a report to the Board annually on the Technical Provisions.

Valuation for Solvency Purposes

Section D

D. Valuation for solvency purposes

This section highlights the way the Company's assets and liabilities are valued differently when calculating own funds (net equity on a Solvency II basis) and when preparing its statutory accounts. The former applies the valuation rules from the Solvency II Directive, and the latter applies valuation rules under Generally Accepted Accounting Principles ('GAAP) in Ireland.

The valuation rules from the Solvency II Directive use International Financial Reporting Standards ('IFRS') as a starting position with various changes applied to move to an economic balance sheet position. Irish GAAP is largely equivalent to the accounting principles applied under IFRS, although differences do exist.

The differences in the valuation bases result in a difference in the Company's net asset value at the yearend of €25.3m (2023 difference: €16.9m).

The table below shows the valuation on a Solvency II basis of the Company's assets and liabilities at 31 December 2024:

€'000	Solvency II Value	Irish GAAP Value	Variance
Assets			
Deferred acquisition costs	-	34,561	(34,561)
Deferred Tax Assets	3,515	7,129	(3,614)
Property, plant & equipment held for own use	18,709	9,667	9,042
Government Bonds	173,864	173,864	-
Corporate Bonds	202,920	202,920	-
Collective Investment Undertakings	30	30	-
Reinsurance recoverables	526,558	638,304	(111,746)
Insurance and intermediaries receivables	20,604	104,277	(83,673)
Reinsurance receivables	54,505	38,463	16,042
Receivables (trade, not insurance)	56,895	74,105	(17,210)
Cash and cash equivalents	26,132	26,132	-
Other assets	23	23	-
Total assets	1,083,755	1,309,475	(225,720)
Liabilities			
Technical provisions – non-life	625,944	763,890	(137,946)
Deposits from reinsurers	215,971	215,971	-
Reinsurance payables	-	59,003	(59,003)
Payables (trade, not insurance)	25,989	80,059	(54,070)
Total liabilities	867,904	1,118,923	(251,019)
Excess of assets over liabilities	215,851	190,552	25,299



D.1 Assets

The table below shows the differences between the valuation of assets under Solvency II valuation rules and the valuations under Irish GAAP at 31 December 2024:

€'000	Solvency II Value	Irish GAAP Value	Variance
Assets			
Deferred acquisition costs	-	34,561	(34,561)
Deferred Tax Assets	3,515	7,129	(3,614)
Property, plant & equipment held for own use	18,709	9,667	9,042
Government Bonds	173,864	173,864	-
Corporate Bonds	202,920	202,920	-
Collective Investment Undertakings	30	30	-
Reinsurance recoverables	526,558	638,304	(111,746)
Insurance and intermediaries receivables	20,604	104,277	(83,673)
Reinsurance receivables	54,505	38,463	16,042
Receivables (trade, not insurance)	56,895	74,105	(17,210)
Cash and cash equivalents	26,132	26,132	-
Other assets	23	23	-
Total assets	1,083,755	1,309,475	(225,720)

The table above shows that the Solvency II valuation of assets at 31 December 2024 was €225.7m lower than the valuation under Irish GAAP.

Insurance liabilities (technical provisions) are measured differently under Solvency II rules compared with Irish GAAP and are also classified differently. To the extent gross liabilities are ceded to reinsurers this will then impact reinsurance recoverable's included within total assets above.

Receivables which are not yet due are reclassified and dealt with as part of the technical provisions, described in section D.2.3.4 below.

Deferred Acquisition Costs are not recognized under Solvency II. Instead, all cashflows related to expenses due to servicing recognised insurance obligations are considered in the best estimate technical provisions.

There were no changes to the approach taken in valuation assets and liabilities under either Solvency II or Irish GAAP during 2024.

The table on the next page summarises the different valuation principles for each class of asset:



D.1 Assets (continued)

Asset Class	
Deferred Acquisition Costs (or "DAC")	Under Irish GAAP, DAC is recognised at cost and amortised systematically over the life of the contracts and tested for impairment at each balance sheet date. Any amoun not recoverable is expensed. Under Solvency II, DAC is not recognized. Instead, all cashflows related to expenses due to servicing recognised insurance obligations are considered in the best estimate technical provisions.
Deferred Tax Assets ("DTA")	Under Irish GAAP DTA are recognised for expected future tax credits. On the Solvency II balance sheet deferred tax is further applied to valuation differences arising between Solvency II and Irish GAAP valuations.
Property, plant & equipment held for own use	These assets are valued in Irish GAAP accounts at historical cost less depreciation Under Solvency II Property, plant and equipment is included at market value which is based on an independent market valuation.
Investments (other than assets held for index-linked and unit-linked contracts)	The Company has an investment portfolio made up of corporate and government bonds. The Company considers that financial assets held are tradeable in active markets. A market is considered active if quoted prices are readily available and those prices represent actual or regularly occurring market transactions on an arm's length basis.
Reinsurance Recoverables	Reinsurance recoverables are valued as part of technical provisions (see details o valuation in section D.2) and separated out for disclosure purposes on the Solvency I balance sheet. Most reinsurance cover is provided by quota share contracts and the recoverables are calculated as a fixed proportion of the gross liabilities. For the non proportional cover, the recoverable amount has been estimated judgmentally, by class, based on the attachment point and limits of each contract and a review of the historical recoveries made under each contract.
Insurance and intermediaries receivables, Reinsurance receivables,	Receivables relating to insurance and intermediaries and reinsurance are valued a amortised cost, consistent with the approach under Irish GAAP, which is no considered to be materially different to the fair value approach under Solvency I valuation principles, since debtor balances are short term, with no discounting impact and convertible into a cash balance.
	Receivables which are not yet due are reclassified and dealt with as part of the technical provisions, described in section D.2.3.4 below These adjustments are evident in the reduction in value between the statutory accounts and the Solvency II value.
Receivables (trade, not insurance)	On an Irish GAAP basis, trade receivables include intragroup receivables, claims floats prepaid insurance premium taxes and other prepayments. These are recognised at fair value.

D.2 Technical Provisions

Technical Provisions represent a valuation of the Company's obligations towards policyholders. Under Solvency II these are required to be calculated as the sum of:

- a) best estimate equal to the probability-weighted average of all future cash-flows, taking account of the time value of money; and
- b) a risk margin equivalent to the amount that an insurance undertaking would be expected to require in order to take over and meet the technical provision obligations.

The calculation of technical provisions considers several factors which can influence the final value. These are discussed in section D.2.1 below.

On a Solvency II basis the total technical provisions at 31 December 2024, including the risk margin, were €99.4m compared to €152.0m on a statutory basis, a difference of 34.6%.

Solvency II Line of Business €m	Total Best Estimate Gross	Risk Margin	Total Gross Technical Provisions	Recoverable s from Reinsurance Contracts	Total Technical Provisions net of Recoverable s
Medical Expenses	16.2	0.2	16.5	(14.1)	2.4
Income Protection	10.6	0.1	10.7	(10.1)	0.6
Motor Vehicle Liability	4.1	0.0	4.1	(3.9)	0.2
Fire and other damage to property	6.7	0.9	7.6	(3.9)	3.7
General liability	368.2	3.7	372.0	(344.8)	27.2
Credit and suretyship	86.6	5.6	92.2	(73.3)	18.9
Legal Expenses	10.9	0.1	11.0	(10.1)	0.9
Assistance	0.4	0.0	0.4	(0.4)	0.0
Miscellaneous financial loss	108.1	4.7	112.8	(66.2)	46.6
Other motor	0.5	0.0	0.5	(0.4)	0.0
Non-Proportional Property	(2.3)	0.6	(1.7)	0.5	(1.1)
Total	609.9	16.0	625.9	(526.6)	99.4



The Company's Irish GAAP reserving policy requires the Actuarial Function to calculate ultimate loss ratios with no margins for prudence or optimism. These loss ratios are calculated at the homogenous class of business level, which is consistent with the way the business is underwritten and managed.

This provides an estimate of the expected future cash outflows from earned business and expected future cash inflows from any associated reinsurance as at the valuation date. An explicit additional margin is added based on the Reserving Committee's recommendations.

The table below summarises how the valuation of technical provisions differs between Solvency II and Irish GAAP.

Unexpired Risks	Under Irish GAAP, premium is earned over the period of the underlying policies having regard to the incidence of risk. Unearned premium represents premium relating to the unexpired period of the policies. Under Solvency II the unearned premium liability is not recognised; however, in its place a Premium Provision is included in technica provisions which reflects expected future claims and expenses netted by expected future premiums on existing policies.
Discounting	Under Irish GAAP discounting is not applied, but under Solvency II all Technica Provisions are discounted to allow for the time value of money.
Recognition of Profit	Under Irish GAAP any profits or losses arising from insurance policies written are recognised over the duration of the policy periods. Under Solvency II rules profits and losses are recognised as the associated policies are recognised.
Margin for Uncertainty/ Events not in Data (ENID's)	Irish GAAP allows an additional margin to be booked over and above the best estimate of technical provisions, which the Company's Reserving Committee considers and recommends. Under Solvency II Technical Provisions must be booked at best estimate, though ENID's must be considered in terms of whether they give rise to the need for additional provisions. An ENID is a type of potential future claim which historical loss data may not necessarily reflect.
Risk Margin	Under Solvency II it is necessary to consider the amount above and beyond the best estimate valuation which one would expect to have to pay another insurer to take or the Company's liabilities. This is the Risk Margin. No such requirement exists under Irish GAAP.

The differences in the basis of calculations between Solvency II and the Financial statements are outlined in further detail in Section D2.3.



D.2.1 Underlying Uncertainties

The Actuarial Function has employed techniques and assumptions that it believes are appropriate for estimating the Technical Provisions. However, the results of these techniques are subject to uncertainty, and it should be recognised that future claim emergence is likely to deviate, perhaps materially, from the estimates.

The uncertainties in the estimates for the Company are increased due to:

- The small size of some classes.
- The lack of development history and hence reliance on benchmarks in some classes.
- Data for some classes is not fully complete or accurate and hence requires significant judgement to arrive at estimated ULRs.
- An increased reserve uncertainty on long-tailed classes. Uncertainty over the losses on remaining unearned exposures, particularly for the classes earning over extended periods such as the Structural Defects business or the Warranty business.
- Uncertainty over the number and magnitude of potential large losses on long tailed business.
- Future claims inflation may differ from assumptions; and
- The existence of profit caps and profit shares for some programmes also adds to the uncertainty in the Company's aggregate estimates.


D.2.2 Solvency II Related Uncertainties

Additional uncertainties because of the Solvency II adjustments include:

- Uncertainty over the number and magnitude of potential large losses (and catastrophes) on all business that is unexpired at the valuation date.
- Uncertainty over the provision for Events Not In Data ("ENIDs") where, by their very nature, there is no data available:
- Potential for deviation in the expected profits on un-incepted and unearned business.
- Potential for deviation in payment patterns from expectations, resulting in an over or underestimation of the level of discount.
- Uncertainty over the volume of un-incepted business.
- Uncertainty surrounding the future premium receivable; and
- Estimation of the Risk Margin due to uncertainty in the run-off of the capital requirements.



D.2.3 Differences between Solvency II valuation and Financial Statements



The Company's Irish GAAP reserving policy requires the Actuarial Function to calculate ultimate loss ratios with no margins for prudence or optimism. An explicit margin is added based on the Reserving Committee recommendations.

The Company is not using the following adjustments in calculating the Technical Provisions:

- Volatility adjustment referred to in Article 77d of Directive 2009/138/EC.
- The transitional risk-free interest rate-term structure referred to Article 308c of Directive 2009/138/EC, and
- The transitional deduction referred to in Article 308d of Directive 2009/138/EC.

The below shows of each material Solvency 2 Line of Business the differences between the Local GAAP Reserves and the Solvency 2 Gross and Net Liabilities.

Solvency II and Irish GAAP valuation Differences €'000	General Liability	Misc Financial Loss	Medical Expenses	Fire and Other Damage to Property	Credit and Suretyship	Other	Total
Gross GAAP Reserves	378,426	184,293	19,282	8,959	158,850	29,383	779,193
SII Adjustments	(10,181)	(76,198)	(3,050)	(2,255)	(72,263)	(5,343)	(169,290)
Gross Best Estimate Provisions	368,245	108,094	16,232	6,705	86,587	24,041	609,903
Net GAAP Reserves	17,659	88,240	3,906	4,084	34,310	3,773	151,972
SII Adjustments	5,763	(46,335)	(1,736)	(1,248)	(21,070)	(4,001)	(68,627)
Net Best Estimate Provisions	23,423	41,905	2,170	2,836	13,240	(228)	83,345
Risk Margin	3,746	4,680	235	858	5,633	889	16,041
Net Technical Provisions	27,169	46,585	2,405	3,694	18,873	661	99,386



Solvency II technical provisions are evaluated on a best estimate cash flow basis with items such as unearned premium reserves removed. To move the Irish GAAP estimates to a Solvency II basis the following adjustments are made:

D.2.3.1 Removal of GAAP items

Solvency II technical provisions are required to be on an actuarial best estimate basis with no implicit margin (or reduction from best estimate). We have assumed the booked Irish GAAP reserves at 31 December 2024 are on this basis and have not recalculated the reserves based on Actuarial ultimate loss ratios. The margin for uncertainty has been removed for Solvency II purposes. Unallocated Loss Adjustment Expenses have been removed for Solvency II purposes. The ULAE is included in the Solvency 2 expenses so it has been removed here to avoid double counting. An adjustment is made for the Nordic Bonus Incentive Scheme as in GAAP the Ceded profit share is part of the Ceded Premium line whereas it forms part of the Ceded Technical Provisions for Solvency II purposes. Expected reinsurance recoveries are allowed for separately for both proportional and non-proportional reinsurance.

D.2.3.2 Recognition of profit in the Unearned Premium Reserve (UPR)

The full amount of unearned premiums is removed from the Technical Provisions. The best estimate of the claim liabilities associated with the UPR are added back and expected reinsurance recoveries are allowed for separately for both proportional and non-proportional reinsurance.

D.2.3.3 Recognition of profits in business written prior to, but incepting after, the valuation date

The premium bound but not incepted (BBNI) serves to reduce the Technical Provisions. The best estimate of the claim liabilities associated with these premiums are added to the Technical Provisions. Expected reinsurance recoveries are allowed for separately for both proportional and non-proportional reinsurance.

D.2.3.4 Allowance for future premiums

Future premium cash flows, premiums that have been written and are either earned or unearned but are not yet due to be paid, are derived from the Company's financial systems for both gross cash inflows and reinsurance cash outflows.

D.2.3.5 Allowance for Events Not In Data (ENID's)

Under Irish GAAP technical provisions only make allowance for items that are implicitly included within the data or are "reasonably foreseeable". Under Solvency II the best estimate must have reference to "all possible outcomes" including latent claims or very extreme high severity, low probability claims. Gross and ceded technical provisions are estimated separately.

D.2.3.6 Allowance for expenses required to service the run-off of the technical provisions

All expenses expected to be incurred in running-off the technical provisions including a proportion of fixed overheads are allowed for. These have been estimated using the latest financial projections and an estimate of the expected time to run-off the Technical Provisions based on the estimated claims payment patterns.



D.2.3.7 Allowance for Reinsurance Bad Debt (non-recoverable reinsurance)

Expected non-payment of reinsurance recoveries continues to be made but this is now calculated on a SII basis. The expected default under Solvency II, which the Company has used, takes into account the timing of the expected payment by reinsurer and hence allows for a change in rating over time. The bad debt provision (earned & unearned) reflects the fact that the majority of the reinsurance is provided by AIIL which is 'A- rated' and hence attracts a correspondingly low bad debt charge. The Company also selected the minimum permissible loss-given-default factor of 50% in estimating this provision. There is also a small bad debt allowance included in the BBNI profits above.

D.2.3.8 Allowance for the future cost of reinsurance in respect of written business

Some future reinsurance purchases will benefit business written at the valuation date and the expected cost of this spend is included in the Technical Provisions.

D.2.3.9 Allowance for the impact of policies lapsing

Some lines of business are subject to policies lapsing (or being cancelled) before the policy has expired or a claim has been made. An allowance for this reduction in future profits (or losses) is made based on historical data.

D.2.3.10 Allowance for future investment income (discounting)

Cash flows are discounted for the time value of money based on the expected timing of all cash flows. The yield curves (discount rates) for major currencies which are used to discount the cash flows are provided by EIOPA.

D.2.3.11 Allowance for a risk margin

This adjustment increases the overall value of the Technical Provisions from the discounted best estimate to an amount equivalent to a theoretical level, needed to transfer the obligations to another insurance undertaking. It is calculated based on a discounted cost-of-capital approach where the initial capital required to support the TPs is assumed to run-off in proportion to the run-off of the Technical Provisions, and a cost of capital of 6% is used in accordance with Solvency II requirements.

D.2.3.12 Reinsurance

The Company has significant reinsurance assets as most lines of business are covered (since mid-2019) by 50% Quota Share reinsurance provided by a 'AA-' rated global third-party reinsurer. Further reinsurance is provided by AmTrust group entities ceding up to 100% of US Surplus Lines, run-off classes and all business with an underwriting year on or before 2021 following the renewal of the LPT reinsurance arrangement on 30 June 2024. The LPT transaction provides the Company with economic certainty around business placed into run-off and protects its capital base from any exposure to reserve deterioration on older underwriting years. As the run-off business performance has been volatile in recent years this positions the Company to return to sustainable profitability moving forward.

The Solvency II Technical Provisions also makes allowance for potential recoveries from non-proportional reinsurance with the most significant covering the Professional Lines and US Liability classes.



D.2.4 Significant changes in assumptions

The main change to assumptions was in respect of the US Surplus Lines business (ISG). Following discussions with the Claims function regarding potential development on the future exposures a more prudent set of assumptions was selected for this programme. This resulted in an increase of €34m (USD38m) in ultimate claims gross of reinsurance during 2024. Net of reinsurance there was no change as the business is 100% ceded.

Most of the on-going business lines developed favourably compared to expectations during 2024 resulting in reductions to the recommended ULRs.

D.3 Other liabilities

The tab le below shows the valuation on a Solvency II basis of the Company's other liabilities at 31 December 2024:

€'000	Solvency II	Irish GAAP	Variance
€ 000	Value	Value	Variance
Deposits from reinsurers	215,971	215,971	-
Reinsurance payables	-	59,003	(59,003)
Payables (trade, not insurance)	25,989	80,059	(54,070)
Total Liabilities	241,960	355,033	(113,073)

The table above shows that the Solvency II valuation of other liabilities at 31 December 2024 was €113.1m lower than the valuation under Irish GAAP.

An explanation of the different valuation approaches between Solvency II and Irish GAAP is included overleaf:

Other Liabilities	
Deposits from reinsurers	Funds withheld are disclosed as Deposits from reinsurers for Solvency II purposes. Under Irish GAAP in the financial statements these balances are presented as part of accruals and deferred income balance.
Insurance & intermediaries payables / Reinsurance payables	Under Irish GAAP reinsurance payables are measured at fair value and are disclosed as other liabilities on the balance sheet. For Solvency II purposes to the extent these relate to unexpired risks they are reported in technical provisions on the basis that they relate to future cashflows.
Payables (trade, not insurance)	These liabilities are also measured at fair value under Irish GAAP and included within liabilities on the balance sheet. For Solvency II purposes to the extent these relate to unexpired risks they are reported in technical provisions on the basis that they relate to future cashflows

D.4 Alternative methods for valuation

The Company does not use any alternative methods for valuation.

D.5 Any other information

None noted.

Capital Management

Section E

E. Capital Management

The Company's capital management objective is to maintain sufficient capital to safeguard the Company's ability to continue as a going concern and to protect the interests of all its customers, investors, regulators, and trading partners while also efficiently deploying capital and managing risk to sustain ongoing business development.

Under Solvency II regulations, the Company is required to maintain capital at a level which is above its Solvency Capital Requirement (or "SCR"). The Minimum Capital Requirement (or "MCR") is a measure which only becomes relevant in a scenario where the capital base has been subject to extreme distress. Accordingly, the SCR value is significantly greater than that of the MCR.

The SCR ratio compares a company's Own Funds to its SCR requirement. While the Company regularly communicates its SCR ratio to the CBI, an SCR ratio below 100% requires immediate reporting in which event the Company must implement a recovery plan to demonstrate the actions it will take to restore its SCR ratio to 100% within 6 months of the breach taking place.

The Company determines its SCR using the Standard Formula and maintains a prudent buffer over the SCR.

The Company's capital position is kept under constant review and is reported quarterly to the Board and to the CBI as part of quantitative Solvency II reporting.

The Company manages its capital resources in line with its Capital Management Policy. The Company manages its Own Funds with the objective of always being able to satisfy both the MCR and the SCR plus a buffer. The target ratio for available capital in excess of the Solvency II SCR is agreed and signed off by the Board. There have been no significant changes to the capital management objectives over the period of this report.

The Company prepares solvency projections for the following three years as part of its business planning process, which forms part of the ORSA. In addition, short-term solvency projections are calculated whenever a significant transaction is considered by the Company.

Solvency calculations are prepared following the end of each quarter and compared with available Own Funds; this is included in the risk function's report to the Risk and Compliance Committee.

E.1 Own funds

The table below lists the components of the company's Own Funds at the year-end:

Own Funds	At 31 Dec 2024 €'000	At 31 Dec 2023 €'000
Ordinary Share Capital	1,946	1,946
Capital Contributions	56,856	56,856
Capital Redemption Reserve	13,270	13,270
Reconciliation Reserve	140,264	124,141
Deferred Tax	3,515	6,741
Own funds	215,851	202,954

The Company's capital resources are made up of Tier 1 and Tier 3 capital instruments. Tier 1 capital comprises fully paid ordinary share capital, capital contributions, a capital redemption reserve and the reconciliation reserve (accumulated profits on a Solvency II valuation basis). The Tier 3 Own Funds represent deferred tax assets.

Tier 3 Own Funds are eligible and available for meeting SCR but not for the MCR. The Company's amount of Own Funds eligible to cover the SCR as of 31 December 2024 and 31 December 2023 are listed in the tables below.

Solvency Overview (in €'000s), as at 31 Dec 2024					
	Tier	Own Funds	Eligible %	Eligible Own Funds	Solvency Ratio
	1	212,336	100%	212,336	
SCR: 129,181	2	0	0%	0	
	3	3,515	100%	3,515	
	Total	215,851		215,851	167%

Solvency Overview (in €'000s), as at 31 Dec 2023					
	Tier C	Own Funds Eligible %	Eligible Own	Solvency	
			Ci Owii i dilas	Funds	Ratio
	1	196,213	100%	196,213	
SCR: 126,832	2	0	0%	0	
	3	6,741	100%	6,741	
	Total	202,954		202,954	160%

The Company's eligible amount of Own Funds to cover the MCR as of 31 December 2024 and 2023 are listed in the tables below.

Solvency Overview (in €'000s), as at 31 Dec 2024					
	Tier	Own Funds	Eligible %	Eligible Own Funds	Solvency Ratio
	1	212,336	100%	212,336	
MCR: 32,295	2	0	0%	0	
	3	3,515	0%	0	
	Total	215,851		212,336	657%

Solvency Overview (in €'000s), as at 31 Dec 2023					
	Tier	Own Funds	Eligible %	Eligible Own Funds	Solvency Ratio
	1	196,213	100%	196,213	
MCR: 31,708	2	0	0%	0	
	3	6,741	0%	0	
	Total	202,954		196,213	619%

As part of the capital management cycle a forward-looking estimate of Own Funds is calculated on a regular basis during the year to monitor expected solvency ratios by comparing with forecast SCR positions at quarter-ends.

There are certain differences between the value of Own Funds under Solvency II and the value of Equity shown in the Company's Financial Statements, prepared under Irish GAAP. These arise due to the difference in valuation of assets and liabilities described in Section D of this report. A reconciliation is shown in section E.1.1 below.

None of the Company's Own Funds are subject to transitional arrangements. The Company has no Ancillary Own Funds.

There are no other deductions made from Own Funds, nor is there any restriction affecting the availability and transferability of Own Funds within the Company.

E1.1 Reconciliation Reserve

The Reconciliation Reserve at the year-end stood at €140.3m compared with €124.1m at the prior year-end:

Reconciliation Reserve	At 31 Dec 2024 €'000	At 31 Dec 2023 €'000
Excess of Assets Over Liabilities	215,851	202,954
Other Basic Own Fund Items	(75,587)	(78,813)
Reconciliation Reserve	140,264	124,141

A reconciliation between equity per the Irish GAAP financial statements and the Solvency II Own Funds is shown below:

Own Funds	At 31 Dec 2024 €'000	At 31 Dec 2023 €'000
Equity per Irish GAAP Financial Statements	190,552	186,024
Valuation Difference	25,299	16,930
Reconciliation Reserve	215,851	202,954

E.2 Solvency capital requirement and minimum capital requirement

The table below shows the Company's SCR and MCR at the year-end:

SCR and MCR Requirements	At 31 Dec 2024 €'000	At 31 Dec 2023 €'000
Solvency Capital Requirement (SCR)	129,181	126,832
Minimum Capital Requirement (MCR)	32,295	31,708

The Company uses an off-the-shelf system to calculate its SCR using the Standard Formula. The Company does not use any Undertaking Specific Parameters, nor does it use simplified calculations for any of the risk modules.

E.2.1 Solvency Capital Requirement

Under Solvency II regulations the SCR is set at a level that ensures that insurers and reinsurers can meet their obligations to policyholders and beneficiaries over the following 12 months with a 99.5%

probability, which limits the possibility of falling into financial ruin to less than once in 200 cases. The formula takes a modular approach, meaning that individual exposure to each risk category is assessed and then aggregated.

The Company's SCR split by risk module as of 31 December 2024 and 31 December 2023 is shown in the table below.

Solvency Capital Requirement (SCR)	At 31 Dec 2024 €'000	At 31 Dec 2023 €'000	Variance €'000
Health NSLT Underwriting Risk	1,705	6,909	(5,204)
Non-Life Underwriting Risk	87,985	85,804	2,181
Market Risk	23,457	21,728	1,729
Counterparty Default Risk	23,725	19,078	4,647
Undiversified Basic SCR	136,872	133,519	3,353
Diversification Credit	(25,988)	(27,862)	1,874
Basic SCR	110,884	105,657	5,227
Operational Risk	18,297	21,175	(2,878)
Standard Formula SCR	129,181	126,832	2,349

During the year the SCR amount increased by €2.3m, or approximately 1.9%. The main drivers for the change are described in Section E.2.3.

E.2.2 Minimum Capital Requirement

Under Solvency II regulations the Minimum Capital Requirement must also be calculated and represents the threshold below which a national regulatory agency would intervene. The MCR is intended to achieve a level of 85% probability of adequacy over one year.

The Solvency II Directive provides regional regulators with several options to address breaches in the MCR, including the complete withdrawal of authorization from selling new policies and forced closure of the Company.

The Company calculates its linear MCR using the prescribed formula. This is then compared with the Absolute floor of the MCR, the MCR cap and the MCR floor. Both the cap and floor are determined using the Standard Formula SCR.



Minimum Capital Requirement (SCR)	At 31 Dec 2024 €'000	At 31 Dec 2023 €'000	Variance €'000
Linear MCR	28,624	29,585	(961)
SCR	129,181	126,832	2,349
MCR cap	58,131	57,074	1,057
MCR floor	32,295	31,708	587
Combined MCR	32,295	31,708	587
Absolute floor of the MCR	4,000	4,000	0
Minimum Capital Requirement	32,295	31,708	587

During the year the MCR amount increased by €0.6m, or approximately 1.9%.

The inputs for the linear MCR are shown in the table below, prescribed factors are applied to these figures to calculate the linear MCR.

MCR Inputs (€'000)	Net (of reinsurance) best estimate technical provisions	Net (of reinsurance) written premiums in the last 12 months
Medical expense insurance	2,170	7,806
Income protection insurance	495	385
Motor vehicle liability insurance	191	0
Other motor insurance	29	0
Fire and other damage to property insurance	2,836	5,184
General liability insurance	23,423	8,613
Credit and suretyship insurance	13,240	22,148
Legal expenses insurance	792	1,806
Assistance	2	0
Miscellaneous financial loss insurance	41,905	90,112

E.2.3 Material Change in SCR and MCR

SCR coverage has increased to 167% at 31 December 2024 from 160% at 31 December 2023. The movement is principally due to the following factors:

- During 2024, the Company renewed its loss portfolio transfer (LPT) to AIIL, an affiliated company domiciled in Bermuda. The LPT now covers an additional policy year between 1st January 2021 and 31st December 2021. This had a reducing impact in the Company's Premium and Reserve Risk, as well as Non-Life Catastrophe Risk;
- Growing budgeted premium volumes in Miscellaneous Financial Loss and Credit and Suretyship increased the Company's Premium Risk;
- The Company's exposure to Italian Accident & Health insurance expired during 2024, which caused most of the decrease in Health Risk by reducing Pandemic Risk within the Health Catastrophe Risk calculation;
- Increases in USD and SEK currency exposure resulted in an increase in Currency Risk, which was partially offset by the impact of reducing EUR interest rates in Interest Rate Risk within Market Risk.
- The Company's Type 2 Counterparty Default Risk exposure increased, mainly due to timing of debtor settlement around year-end; and



• During 2024, the Company's IR GAAP profit of €14.5m and gains on Solvency II valuation of Own Funds of €8.4m were offset by €10.0m of dividends distributed to its parent.

The increase in MCR coverage to 657% at 31 December 2024 from 619% at 31 December 2023 is driven by the same movements influencing the SCR movement in the year.

E.3 Use of duration-based equity risk sub-module in the calculation of Solvency Capital

The Company does not use the duration-based equity risk sub-module in the calculation of its SCR.

E.4 Difference between the Standard Formula and the Internal Model used

The Company does not have an Internal Model to calculate its SCR.

E.5 Non-compliance with the Minimum Capital Requirement and non-compliance with the Solvency Capital Requirement

The Company has been in compliance with the MCR and SCR throughout the reporting period.

E.6 Any other information

None noted.

Appendix

Quantitative Reporting Templates

S.02.01 Balance Sheet, Assets (in €, as of December 31)

Assets		Solvency II value
Goodwill	0010	0
Deferred acquisition costs R(0020	0
Intangible assets RG	0030	0
Deferred tax assets R(0040	3,514,741
Pension benefit surplus RC	0050	0
Property, plant & equipment held for own use	0060	18,708,782
Investments (other than assets held for index-linked and unit-linked contracts)	0070	376,813,805
Property (other than for own use)	080	0
Holdings in related undertakings, including participations	0090	0
Equities RC	0100	0
Equities — listed RO	0110	0
Equities — unlisted	0120	0
Bonds	0130	376,783,657
Government Bonds RO	0140	173,863,679
Corporate Bonds RO	0150	202,919,979
Structured notes RO	0160	0
Collateralised securities RO	0170	0
Collective Investments Undertakings	0180	30,148
Derivatives RO	0190	0
Deposits other than cash equivalents	0200	0
Other investments RO	0210	0
Assets held for index-linked and unit-linked contracts	0220	0
Loans and mortgages RO	0230	0
Loans on policies RO	0240	0
Loans and mortgages to individuals	0250	0
Other loans and mortgages	0260	0
Reinsurance recoverables from:	0270	526,558,181
Non-life and health similar to non-life	0280	526,558,181
Non-life excluding health	0290	502,429,660
Health similar to non-life Ro	0300	24,128,522
Life and health similar to life, excluding health and index-linked and unit-linked	0310	0
Health similar to life RO	0320	0
Life excluding health and index-linked and unit-linked	0330	0
Life index-linked and unit-linked	0340	0
Deposits to cedants RO	0350	0
Insurance and intermediaries receivables	0360	20,603,725
Reinsurance receivables RO	0370	54,505,386
Receivables (trade, not insurance)	0380	56,895,457
Own shares (held directly)	0390	0
Amounts due in respect of own fund items or initial fund called up but not yet paid in	0400	0
Cash and cash equivalents RG	0410	26,131,709
Any other assets, not elsewhere shown	0420	22,810
Total assets RG	0500	1,083,754,598



Annex 1 S.02.01 Balance Sheet, Liabilities (in €, as of December 31)

Technical provisions — non-life (encluding leasility) RSS, 394,173 SSS, 374,170 Technical provisions calculated as a whole RSS, 30 958,817,170 Best Cistinate RSS, 30 958,815,004 RSA, margin RSS, 30,000 15,707,447 Technical provisions calculated as a whole RSS, 300,000 15,707,447 Technical provisions calculated as a whole RSS, 300,000 15,707,447 Technical provisions calculated as a whole RSS, 300,000 0 Risk margin Risk margin RISK MSS, 300,000 0 Technical provisions calculated as a whole 0500,00 0 Rest Strands RSS, 300,000 0 Technical provisions calculated as a whole 0500,00 0 Rest Strands RSS, 500,000 0 Technical provisions RSS, 500,000 <	Liabilities		Solvency II value
Estimate provisions calculated as a whole 90.500 583.096.43	Technical provisions — non-life	R0510	625,944,193
Risk margin 80540 \$83,305,648 Technical provisions – health (similar to non-life) 80550 27,222,063 Technical provisions – health (similar to non-life) 80500 27,222,063 Best Strained 80500 20,334,443 Best Strained 80500 333,443 Inchinical provisions — left (exclusing index elivated and unit-linked) 80500 0 Technical provisions — health (similar to life) 80500 0 Technical provisions — health (similar to life) 80500 0 Technical provisions — health (similar to life) 80500 0 Technical provisions — health (similar to life) 80500 0 Technical provisions — health (similar to life) 80500 0 Technical provisions — health (similar to life) 80500 0 Technical provisions — health (similar to life) 80500 0 Technical provisions — health (similar to life) 80500 0 Technical provisions calculated as a whole 80500 0 Technical provisions — health (similar to life) 80500 0 Technical provisions — health (similar to	Technical provisions — non-life (excluding health)	R0520	598,817,130
Risk mergin	Technical provisions calculated as a whole	R0530	0
Technical provisions - Provision (similar to non-life)	Best Estimate	R0540	583,109,643
Technical provisions calculated as a whole Risk managin Risk	Risk margin	R0550	15,707,487
Technical provisions calculated as a whole Risk margin	Technical provisions — health (similar to non-life)	R0560	27,127,063
Bits Estimate PROSED 226,779,620 Technical provisions — left (excluding index-linked) R000 0 Technical provisions — leaft (excluding index-linked) R0010 0 Technical provisions — leaft (inflint to life) R0010 0 Technical provisions — leaft (inflint to life) R0020 0 Bits Estimate R0050 0 0 Bits A margin R0060 0 0 Technical provisions — leaft (inflint to life) R0060 0 0 Technical provisions — leaft (inflint to life) R0060 0 0 Technical provisions — life (including life) R0060 0 0 Technical provisions — life (including life) R0060 0 0 Technical provisions acclulated as a whole R0070 0 0 Best Estimate R0070 0 0 0 Technical provisions acclulated as a whole R0070 0 0 0 0 0 0 0 0 0 0 0 0 0 0			0
Received provisions		R0580	26,793,620
Technical provisions — Intel textuding Index-linked and unit-linked)			
Technical provisions – health (similar to life) Technical provisions calculated as a whole Best Estimate Bisk stressma Bisk margin Technical provisions – life (excluding health and index-linked and unit-linked) Technical provisions – life (excluding health and index-linked and unit-linked) Technical provisions calculated as a whole Best Estimate Bisk margin Bisk margin Risk margin Risk margin Risk margin Rosso Technical provisions – Index-linked and unit-linked Risk margin Rosso Technical provisions – Index-linked and unit-linked Rosso Rosso Technical provisions – Index-linked and unit-linked Rosso			·
Technical provisions calculated as a whole 806.00			
Best Stimate R0600 0 Risk margin R0600 0 Technical provisions calculated as a whole R0600 0 Best Stimate R0600 0 Risk margin R0600 0 Risk margin R0600 0 Technical provisions – index-linked and unit-linked R0600 0 Technical provisions – index-linked and unit-linked R0000 0 Technical provisions – index-linked and unit-linked R0000 0 Bisk margin R0700 0 Bisk margin R0700 0 Bisk margin R0700 0 Charterinal provisions R0730 0 Charterinal provisions R0730 0 Charterinal provisions R0700 0 Contingent liabilities R0700 0 Provisions other than technical provisions R0700 0 Deposits from reinsurers R0700 0 0 Deposits from reinsurers R0700 0 0 Debts cowel to credit			
Risk margin	·		
Technical provisions — life (excluding health and index linked and unit-linked) Technical provisions calculated as a whole Best Estimate R0670 0 0 Risk margin Technical provisions calculated as a whole R0660 0 0 Technical provisions calculated as a whole R0700 0 0 Best Estimate R0700 0 0 Best Estimate R1700 0 0 Best Estimate R1700 0 0 Contingent liabilities R1700 0 0 Contingent liabilities content than domestically R1700 0 0 Contingent liabilities (extent extention in resident in domestically R1700 0 0 Contingent liabilities (extention in resident in the euro area other than domestic R1700 0 0 Contingent liabilities (extention in resident in the euro area other than domestic R1700 0 0 Contingent liabilities (extention in institutions resident in the e			
Technical provisions calculated as a whole 806670 0 0 0 0 0 0 0 0 0			
Rest Estimate R0670 0 Risk margin R0680 0 Technical provisions – index-linked and unit-linked R0700 0 Technical provisions calculated as a whole R0700 0 Best Estimate R0710 0 Risk margin R0720 0 Other technical provisions R0730 0 Contingent liabilities R0740 0 Provisions there than technical provisions R0750 0 Persion benefit obligations R0750 0 Persion benefit obligations R0760 0 Deposits from reinsurers R0770 215,970,525 Deferred tas Itabilities R0770 215,970,525 Deferred tas Itabilities R0770 215,970,525 Deferred tas Itabilities R0770 0 Debts owed to credit institutions R0800 0 Debts owed to credit institutions resident in the euro area other than domestic R0800 0 Debts owed to credit institutions resident in the euro area other than domestic R0801 0 <th< td=""><td></td><td></td><td></td></th<>			
Risk margin			
Technical provisions – index-linked and unit-linked Technical provisions calculated as a whole Best Estimate Best Estimate Risk margin Risk margin Risk margin Risk margin Roman Roman			
Technical provisions calculated as a whole Best Estimate Bisk margin Other technical provisions RO700 Other technical provisions RO800 Other technical liabilities (abe scurtles issued) RO800 Other technical lia	-		
Best Estimate RO710 0 Risk margin RO720 0 Other technical provisions RO730 0 Octningent liabilities RO740 0 Provisions other than technical provisions RO740 0 Persion benefit obligations RO750 0 Openosits from reinsurers RO770 215,790,925 Deferred tax liabilities RO780 0 Deferred tax liabilities RO790 0 Debts owed to credit institutions RO890 0 Debts owed to credit institutions resident domestically ER0801 0 Debts owed to credit institutions resident in rest of the world ER0802 0 Debts owed to oredit institutions resident in rest of the world ER0803 0 Inancial liabilities to obte made does doe to credit institutions RE0811 0 Debts owed to non-credit institutions RE0811 0 Debts owed to non-credit institutions resident in the euro area other than domestic ER0812 0 Debts owed to non-credit institutions resident in rest of the world ER0813 0	·		
Risk margin R0720 0 Other technical provisions R0730 0 Contingent liabilities R0740 0 Provisions other than technical provisions R0750 0 Persion benefit obligations R0760 0 Deposits from reinsurers R0770 215,970,925 Deferred tax liabilities R0780 0 Derivatives R0780 0 Derivatives R0780 0 Debts owed to credit institutions resident domestically R0800 0 Debts owed to credit institutions resident in the euro area other than domestic E0802 0 Debts owed to credit institutions resident in rest of the world E0802 0 Financial liabilities other than debts owed to credit institutions resident in rest of the world E0801 0 Debts owed to non-credit institutions resident in the euro area other than domestic E0801 0 Debts owed to non-credit institutions resident in the euro area other than domestic E0801 0 Debts owed to non-credit institutions resident in rest of the world E0802 0 Other financial liabiliti	·		
Other technical provisions R0730 0 0 Contingent liabilities R0740 0 0 Provisions other than technical provisions R0750 0 0 Provisions other than technical provisions R0750 0 0 Persion benefit obligations R0760 0 0 Persion benefit obligations R0760 0 0 Persion benefit obligations R0760 0 0 Persion benefit obligations R0770 215,970,925 0 0 Persion benefit obligations R0770 0 0 Persion benefit obligations R0800 0 0 Persion R0800 0 Persion			
Contingent liabilities Provisions other than technical provisions RO750 Pension benefit colligations RO760 Pension from reinsurers RO770 Pension benefit colligations RO780 Pension treinsurers RO770 Pension treinsurers RO780 Pension treinsurers RO780 Pension treinsurers RO800 Pension treinsurer			
Provisions other than technical provisions 800 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			
Pension benefit obligations R0760 0 Deposits from reinsurers R0770 215,970,925 Deferred tax liabilities R0780 0 Derivatives R0780 0 Debts owed to credit institutions R0800 0 Debts owed to credit institutions resident domestically ER0801 0 Debts owed to credit institutions resident in the euro area other than domestic ER0802 0 Debts owed to credit institutions resident in rest of the world ER0803 0 Debts owed to credit institutions resident in rest of the world ER0803 0 Debts owed to credit institutions resident in rest of the world ER0803 0 Debts owed to non-credit institutions resident in rest of the world ER0803 0 Debts owed to non-credit institutions resident domestically ER0811 0 Debts owed to non-credit institutions resident domestically ER0811 0 Debts owed to non-credit institutions resident in the euro area other than domestic ER0813 0 Debts owed to non-credit institutions resident in rest of the world ER0813 0 Debts owed to non-credit institutions resident in rest of the world ER0813 0 Other financial liabilities (debt securities issued) ER0813 0 Insurance & intermediaries payables R0830 0 Insurance & intermediaries payables R0830 0 Reinsurance payables R0830 0 R0	-		
Deposits from reinsurers R0770 215,970,925 Deferred tax liabilities R0780 0 Derivatives R0790 0 Debts owed to credit institutions Debts owed to credit institutions resident in the euro area other than domestic R0800 0 Debts owed to credit institutions resident in the euro area other than domestic R0800 0 Debts owed to credit institutions resident in rest of the world R0800 0 Debts owed to credit institutions resident in rest of the world R0800 0 Debts owed to credit institutions resident in rest of the world R0800 0 Debts owed to non-credit institutions resident in rest of the world R0800 0 Debts owed to non-credit institutions R0810 0 Debts owed to non-credit institutions resident in the euro area other than domestic R0811 0 Debts owed to non-credit institutions resident in the euro area other than domestic R0811 0 Debts owed to non-credit institutions resident in rest of the world R0810 0 Debts owed to non-credit institutions resident in rest of the world R0810 0 Debts owed to non-credit institutions resident in rest of the world R0810 0 Debts owed to non-credit institutions resident in rest of the world R0810 0 Debts owed to non-credit institutions resident in rest of the world R0810 0 Debts owed to non-credit institutions resident in rest of the world R0810 0 Debts owed to non-credit institutions resident in rest of the world R0810 0 Debts owed to non-credit institutions resident in rest of the world R0810 0 Debts owed to non-credit institutions resident in rest of the world R0810 0 Debts owed to ron-credit institutions resident in rest of the world R0810 0 Debts owed to ron-credit institutions resident in rest of the world R0810 0 Debts owed to ron-credit institutions resident in rest of the world R0810 0 Debts owed to ron-credit institutions resident in rest of the world R0810 0 Debts owed to ron-credit institutions resident in rest of the world R0810 0 Debts owed to ron-credit institutions resident in rest of the world R0810 0 Debts owed to ron-credit institutions resident in rest of the world R0810 0 De			
Deferred tax liabilities R0780 0 Derivatives R0790 0 Derivatives R0800 0 Debts owed to credit institutions resident domestically R0800 0 Debts owed to credit institutions resident in the euro area other than domestic R0800 0 Debts owed to credit institutions resident in the euro area other than domestic R0800 0 Debts owed to credit institutions resident in rest of the world R0800 0 Debts owed to credit institutions resident in rest of the world R0800 0 Debts owed to credit institutions resident in rest of the world R0800 0 Debts owed to non-credit institutions R0810 0 Debts owed to non-credit institutions resident domestically R0811 0 Debts owed to non-credit institutions resident domestically R0801 0 Debts owed to non-credit institutions resident in the euro area other than domestic R0811 0 Debts owed to non-credit institutions resident in rest of the world R0811 0 Debts owed to non-credit institutions resident in rest of the world R0811 R0811 0 Debts owed to non-credit institutions resident in rest of the world R0811 R08			
Derivatives R0790 0 Debts owed to credit institutions resident domestically Debts owed to credit institutions resident in the euro area other than domestic R0800 0 Debts owed to credit institutions resident in the euro area other than domestic R08002 0 Debts owed to credit institutions resident in rest of the world R08003 0 Financial liabilities other than debts owed to credit institutions R08003 0 Debts owed to non-credit institutions R08000 0 Debts owed to non-credit institutions R08000 0 Debts owed to non-credit institutions resident domestically R08000 0 Debts owed to non-credit institutions resident in the euro area other than domestic R08010 0 Debts owed to non-credit institutions resident in the euro area other than domestic R08010 0 Debts owed to non-credit institutions resident in the euro area other than domestic R08010 0 Debts owed to non-credit institutions resident in rest of the world R08010 0 Debts owed to non-credit institutions resident in rest of the world R08010 0 Debts owed to non-credit institutions resident in rest of the world R08010 0 Debts owed to non-credit institutions resident in rest of the world R08010 0 Debts owed to non-credit institutions resident in rest of the world R08010 0 Debts owed to non-credit institutions resident domestically R0800 0 Debts owed to non-credit institutions resident in the euro area other than domestic R08010 0 Debts owed to non-credit institutions resident in the euro area other than domestic R08010 0 Debts owed to non-credit institutions resident in the euro area other than domestic R08010 0 Debts owed to non-credit institutions resident in the euro area other than domestic R08010 0 Debts owed to non-credit institutions resident in the euro area other than domestic R08010 0 Debts owed to non-credit institutions resident in the euro area other than domestic R08010 0 Debts owed to non-credit institutions resident in the euro area other than domestic R08010 0 Debts owed to non-credit institutions resident in the euro area other than domestic R08010 0 Debts			
Debts owed to credit institutions R0800 0 Debts owed to credit institutions resident domestically ER0801 0 Debts owed to credit institutions resident in the euro area other than domestic ER0802 0 Debts owed to credit institutions resident in the euro area other than domestic ER0803 0 Debts owed to rendit institutions resident in rest of the world ER0803 0 Financial liabilities other than debts owed to credit institutions ER0811 0 Debts owed to non-credit institutions resident domestically ER0812 0 Debts owed to non-credit institutions resident in the euro area other than domestic ER0813 0 Debts owed to non-credit institutions resident in rest of the world ER0814 0 Other financial liabilities (debt securities issued) ER0815 0 Insurance & intermediaries payables R0820 0 Reinsurance payables R0820 0 Payables (trade, not insurance) R0840 25,988,403 Subordinated liabilities R0850 0 Non-negotiable instruments held by credit institutions resident in the euro area other than domestic ER0851 0 Non-negotiable instruments held by ron-credit institutions resident in the euro area other than domestic ER0852 0 Non-negotiable instruments held by non-credit insti			
Debts owed to credit institutions resident domestically Debts owed to credit institutions resident in the euro area other than domestic Debts owed to credit institutions resident in rest of the world Financial liabilities other than debts owed to credit institutions Debts owed to non-credit institutions Debts owed to non-credit institutions Debts owed to non-credit institutions resident domestically Debts owed to non-credit institutions resident domestically Debts owed to non-credit institutions resident in the euro area other than domestic Debts owed to non-credit institutions resident in rest of the world Other financial liabilities (debt securities issued) ER0811 Debts owed to non-credit institutions resident in rest of the world Other financial liabilities (debt securities issued) ER0815 Debts owed to non-credit institutions resident in rest of the world ER0815 Debts owed to non-credit institutions resident of the world ER0815 Debts owed to non-credit institutions resident of the world ER0815 Debts owed to non-credit institutions resident of the world ER0815 Debts owed to non-credit institutions resident of omestically Robertial (abilities) Rob			
Debts owed to credit institutions resident in the euro area other than domestic Debts owed to credit institutions resident in rest of the world Financial liabilities other than debts owed to credit institutions Debts owed to non-credit institutions Debts owed to non-credit institutions Debts owed to non-credit institutions resident domestically Debts owed to non-credit institutions resident in the euro area other than domestic Debts owed to non-credit institutions resident in rest of the world Debts owed to non-credit institutions resident in rest of the world Other financial liabilities (debt securities issued) Insurance & intermediaries payables Ross20 O Reinsurance & intermediaries payables Ross30 D Payables (trade, not insurance) Subordinated liabilities Non-negotiable instruments held by credit institutions resident in the euro area other than domestic Ross51 Non-negotiable instruments held by credit institutions resident in the euro area other than domestic Ross53 Non-negotiable instruments held by non-credit institutions resident in rest of the world Ross64 Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic Ross55 Non-negotiable instruments held by non-credit institutions resident in rest of the world Ross66 Non-negotiable instruments held by non-credit institutions resident in rest of the world Ross66 Non-negotiable instruments held by non-credit institutions resident in rest of the world Ross66 Non-negotiable instruments held by non-credit institutions resident in rest of the world Ross66 Non-negotiable instruments held by non-credit institutions resident in rest of the world Ross66 Ross60 R			
Debts owed to credit institutions resident in rest of the world Financial liabilities other than debts owed to credit institutions Debts owed to non-credit institutions Debts owed to non-credit institutions resident domestically Debts owed to non-credit institutions resident in the euro area other than domestic Debts owed to non-credit institutions resident in the euro area other than domestic Debts owed to non-credit institutions resident in rest of the world Debts owed to non-credit institutions resident in rest of the world Debts owed to non-credit institutions resident in rest of the world Other financial liabilities (debt securities issued) Insurance & intermediaries payables Rosea R	Debts owed to credit institutions resident domestically		
Financial liabilities other than debts owed to credit institutions Debts owed to non-credit institutions resident domestically Debts owed to non-credit institutions resident in the euro area other than domestic ER0812 Debts owed to non-credit institutions resident in the euro area other than domestic ER0813 Debts owed to non-credit institutions resident in the euro area other than domestic ER0813 Debts owed to non-credit institutions resident in rest of the world ER0814 Other financial liabilities (debt securities issued) ER0815 O Insurance & intermediaries payables R0820 R0830 O Reinsurance payables R0830 O Reinsurance payables R0840 Z5,988,403 Subordinated liabilities R0850 O Non-negotiable instruments held by credit institutions resident domestically Non-negotiable instruments held by credit institutions resident in the euro area other than domestic R0851 Non-negotiable instruments held by credit institutions resident in rest of the world R0852 Non-negotiable instruments held by non-credit institutions resident in rest of the world R0855 Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic R0855 Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic R0855 Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic R0855 Non-negotiable instruments held by non-credit institutions resident in rest of the world Subordinated liabilities not in Basic Own Funds R0860 O Any other liabilities in Basic Own Funds R0870 O R87,903,522	Debts owed to credit institutions resident in the euro area other than domestic	ER0802	0
Debts owed to non-credit institutions Debts owed to non-credit institutions resident domestically Debts owed to non-credit institutions resident in the euro area other than domestic Debts owed to non-credit institutions resident in rest of the world Debts owed to non-credit institutions resident in rest of the world Other financial liabilities (debt securities issued) Insurance & intermediaries payables Ro820 Debts owed intermediaries payables Ro820 Reinsurance payables Ro830 Ro830 Royables (trade, not insurance) Ro840 Subordinated liabilities Ro850 Non-negotiable instruments held by credit institutions resident domestically Non-negotiable instruments held by credit institutions resident in rest of the world Non-negotiable instruments held by non-credit institutions resident domestically Non-negotiable instruments held by non-credit institutions resident in rest of the world Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic Ro855 Non-negotiable instruments held by non-credit institutions resident in rest of the world Ro856 Ro856 Ro860 Ro8	Debts owed to credit institutions resident in rest of the world	ER0803	0
Debts owed to non-credit institutions resident domestically Debts owed to non-credit institutions resident in the euro area other than domestic Debts owed to non-credit institutions resident in rest of the world ER0814 Other financial liabilities (debt securities issued) Insurance & intermediaries payables R0820 R0820 R0820 R0820 R0820 R0820 R0820 R0830 R0830 R0830 R0830 R0830 R0830 R0840 Payables (trade, not insurance) Subordinated liabilities Non-negotiable instruments held by credit institutions resident domestically Non-negotiable instruments held by credit institutions resident in the euro area other than domestic R0852 Non-negotiable instruments held by credit institutions resident in rest of the world R0853 Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic R0853 Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic R0855 Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic R0855 Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic R0855 Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic R0855 R0850 R0	Financial liabilities other than debts owed to credit institutions	R0810	0
Debts owed to non-credit institutions resident in the euro area other than domestic Debts owed to non-credit institutions resident in rest of the world Other financial liabilities (debt securities issued) Insurance & intermediaries payables Ros20 O Reinsurance payables Ros30 Payables (trade, not insurance) Non-negotiable instruments held by credit institutions resident domestically Non-negotiable instruments held by credit institutions resident in the euro area other than domestic Non-negotiable instruments held by credit institutions resident domestically Non-negotiable instruments held by credit institutions resident in the euro area other than domestic Non-negotiable instruments held by credit institutions resident in rest of the world Ros50 Non-negotiable instruments held by non-credit institutions resident domestically Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic Ros55 Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic Ros66 Non-negotiable instruments held by non-credit institutions resident in rest of the world Subordinated liabilities not in Basic Own Funds Ros60 O Any other liabilities, not elsewhere shown Ros80 O Total liabilities Ros90 Ros9	Debts owed to non-credit institutions	ER0811	0
Debts owed to non-credit institutions resident in rest of the world Other financial liabilities (debt securities issued) Insurance & intermediaries payables Reinsurance & intermediaries payables Reinsurance payables Reinsurance payables (trade, not insurance) Reinsurance & Ro840 Ro840 Ro840 Ro850 Ro850 Subordinated liabilities Ro850 Non-negotiable instruments held by credit institutions resident domestically Ro850 Ro851 Ro851 Ro852 Ro852 Ro852 Ro853 Ro860 Ro850 Ro860 Ro860 Subordinated liabilities not in Basic Own Funds Ro860 Ro860 Any other liabilities, not elsewhere shown Ro880 R	Debts owed to non-credit institutions resident domestically	ER0812	0
Other financial liabilities (debt securities issued) Insurance & intermediaries payables R0820 Reinsurance payables R0830 Payables (trade, not insurance) Subordinated liabilities Non-negotiable instruments held by credit institutions resident domestically Non-negotiable instruments held by credit institutions resident in the euro area other than domestic R0851 Non-negotiable instruments held by credit institutions resident in rest of the world R0852 Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic R0853 Non-negotiable instruments held by non-credit institutions resident domestically R0854 Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic R0855 Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic R0855 Non-negotiable instruments held by non-credit institutions resident in rest of the world Subordinated liabilities not in Basic Own Funds R0860 O Any other liabilities, not elsewhere shown R0880 O Total liabilities R0900 867,903,522	Debts owed to non-credit institutions resident in the euro area other than domestic	ER0813	0
Reinsurance & intermediaries payables Reinsurance payables Reinsurance payables Reinsurance payables Rosso Payables (trade, not insurance) Rosso Subordinated liabilities Rosso Non-negotiable instruments held by credit institutions resident domestically Non-negotiable instruments held by credit institutions resident in the euro area other than domestic Rosso Non-negotiable instruments held by credit institutions resident in rest of the world Rosso Non-negotiable instruments held by non-credit institutions resident domestically Ron-negotiable instruments held by non-credit institutions resident domestically Ron-negotiable instruments held by non-credit institutions resident domestically Ron-negotiable instruments held by non-credit institutions resident in the euro area other than domestic Rosso Non-negotiable instruments held by non-credit institutions resident in rest of the world Rosso Subordinated liabilities not in Basic Own Funds Rosso O Subordinated liabilities in Basic Own Funds Rosso O Any other liabilities Rosso O Rosso O Rosso O Rosso Rosso Rosso O Rosso Rosso Rosso Rosso O Rosso Ro	Debts owed to non-credit institutions resident in rest of the world	ER0814	0
Reinsurance payables Payables (trade, not insurance) RO840 Payables (trade, not insurance) RO840 Subordinated liabilities RO850 O Non-negotiable instruments held by credit institutions resident domestically Non-negotiable instruments held by credit institutions resident in the euro area other than domestic RO852 Non-negotiable instruments held by credit institutions resident in rest of the world RO853 Non-negotiable instruments held by non-credit institutions resident domestically RO854 Non-negotiable instruments held by non-credit institutions resident domestically RO855 Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic RO855 RO856 O Subordinated liabilities not in Basic Own Funds RO860 O Subordinated liabilities in Basic Own Funds RO870 O Any other liabilities RO880 O Total liabilities RO990 RO890 RO89	Other financial liabilities (debt securities issued)	ER0815	0
Payables (trade, not insurance) Subordinated liabilities R0850 Non-negotiable instruments held by credit institutions resident domestically Non-negotiable instruments held by credit institutions resident in the euro area other than domestic R0851 Non-negotiable instruments held by credit institutions resident in rest of the world R0852 Non-negotiable instruments held by non-credit institutions resident domestically R0853 Non-negotiable instruments held by non-credit institutions resident domestically R0854 Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic ER0855 Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic ER0855 O Subordinated liabilities not in Basic Own Funds R0860 O Any other liabilities in Basic Own Funds R0870 O Total liabilities R0900 867,903,522	Insurance & intermediaries payables	R0820	0
Non-negotiable instruments held by credit institutions resident in the euro area other than domestic Non-negotiable instruments held by credit institutions resident in the euro area other than domestic Non-negotiable instruments held by credit institutions resident in rest of the world Non-negotiable instruments held by non-credit institutions resident domestically Non-negotiable instruments held by non-credit institutions resident domestically Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic ER0855 Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic ER0855 O Subordinated liabilities not in Basic Own Funds R0860 O Any other liabilities in Basic Own Funds R0870 O Total liabilities R0900 867,903,522	Reinsurance payables	R0830	0
Non-negotiable instruments held by credit institutions resident domestically Non-negotiable instruments held by credit institutions resident in the euro area other than domestic Non-negotiable instruments held by credit institutions resident in rest of the world ROB53 Non-negotiable instruments held by non-credit institutions resident domestically Non-negotiable instruments held by non-credit institutions resident domestically Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic ROB55 Non-negotiable instruments held by non-credit institutions resident in rest of the world ER0855 O Subordinated liabilities not in Basic Own Funds ROB60 O Any other liabilities, not elsewhere shown ROB80 O Total liabilities ROB90 867,903,522	Payables (trade, not insurance)	R0840	25,988,403
Non-negotiable instruments held by credit institutions resident in the euro area other than domestic Non-negotiable instruments held by credit institutions resident in rest of the world Non-negotiable instruments held by non-credit institutions resident domestically Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic R0855 Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic R0855 Non-negotiable instruments held by non-credit institutions resident in rest of the world R0856 Subordinated liabilities not in Basic Own Funds R0860 O Subordinated liabilities in Basic Own Funds R0870 Any other liabilities, not elsewhere shown R0880 Total liabilities R0900 867,903,522	Subordinated liabilities	R0850	0
Non-negotiable instruments held by credit institutions resident in rest of the world Non-negotiable instruments held by non-credit institutions resident domestically Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic ER0855 Non-negotiable instruments held by non-credit institutions resident in rest of the world ER0856 Subordinated liabilities not in Basic Own Funds Subordinated liabilities in Basic Own Funds Any other liabilities, not elsewhere shown R0800 Total liabilities R0900 867,903,522	Non-negotiable instruments held by credit institutions resident domestically	ER0851	0
Non-negotiable instruments held by non-credit institutions resident domestically Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic Non-negotiable instruments held by non-credit institutions resident in rest of the world Subordinated liabilities not in Basic Own Funds Subordinated liabilities in Basic Own Funds Any other liabilities, not elsewhere shown Total liabilities R0800 R0800 R0800 R0800 R0800 R0800 R0800 R0800 R0800 R0900 R0900 R67,903,522	Non-negotiable instruments held by credit institutions resident in the euro area other than domestic	ER0852	0
Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic Non-negotiable instruments held by non-credit institutions resident in rest of the world Subordinated liabilities not in Basic Own Funds Any other liabilities, not elsewhere shown Total liabilities R0800 R0800 R0800 0 867,903,522	Non-negotiable instruments held by credit institutions resident in rest of the world	ER0853	0
Non-negotiable instruments held by non-credit institutions resident in rest of the world Subordinated liabilities not in Basic Own Funds Subordinated liabilities in Basic Own Funds Any other liabilities, not elsewhere shown Total liabilities R0800 0 0 0 0 0 0 0 0 0 0 0 0	Non-negotiable instruments held by non-credit institutions resident domestically	ER0854	0
Subordinated liabilities not in Basic Own Funds Subordinated liabilities in Basic Own Funds Any other liabilities, not elsewhere shown R0880 Total liabilities R0900 867,903,522	Non-negotiable instruments held by non-credit institutions resident in the euro area other than domestic	ER0855	0
Subordinated liabilities in Basic Own Funds Any other liabilities, not elsewhere shown Total liabilities R0870 0 R0880 0 867,903,522	Non-negotiable instruments held by non-credit institutions resident in rest of the world	ER0856	0
Any other liabilities, not elsewhere shown R0880 0 Total liabilities R0900 867,903,522	Subordinated liabilities not in Basic Own Funds	R0860	0
Total liabilities R0900 867,903,522	Subordinated liabilities in Basic Own Funds	R0870	0
	Any other liabilities, not elsewhere shown	R0880	0
Excess of Assets over Liabilities R1000 215,851,076	Total liabilities	R0900	867,903,522
	Excess of Assets over Liabilities	R1000	215,851,076



Annex 1
S.04.05.21 Premiums, claims and expenses by country (in €, as of December 31)

Name of the country		Home Country	SE	DE	PL	DK	FR
		C0010					
Premiums written (gross)							
Gross Written Premium (direct)	R0020	3,715,134	48,907,469	46,538,443	25,965,133	37,631,939	34,765,794
Gross Written Premium (proportional Reinsurance)	R0021	0	2,625	101,634	19,285,810	393,726	1,119,569
Gross Written Premium (non-proportional Reinsurance)	R0022						
Premiums earned (gross)							
Gross Earned Premium (direct)	R0030	5,374,243	51,910,066	47,777,310	18,145,518	37,821,026	36,734,203
Gross Earned Premium (proportional Reinsurance)	R0031	55,390	3,587	54,729	4,079,821	443,066	1,216,888
Gross Earned Premium (non-proportional Reinsurance)	R0032						
Claims incurred							
Claims Incurred (direct)	R0040	-1,644,837	17,281,937	8,642,331	8,325,060	32,466,154	41,344,112
Claims Incurred (proportional Reinsurance)	R0041	-45,661	-1,538	31,988	3,459,731	98,907	-137,505
Claims Incurred (non-proportional Reinsurance)	R0042						
Expenses incurred (gross							
Gross Expenses Incurred (direct)	R0050	36,591,589	20,986,405	8,535,976	2,532,755	3,597,453	2,401,781
Gross Expenses Incurred (proportional Reinsurance)	R0051	11,423	1,306	18,517	0	129,594	-207,746
Gross Expenses Incurred (non-proportional Reinsurance)	R0052						

S.05.01 Premiums, claims and expenses by Line of Business – Non-Life (in €, as of December 31)

					Direct business and accepte	d			
				I	Direct business and accepte	a proportional reinsurance	1		
		Medical expense insurance	Income protection insurance	Workers' compensation insurance	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport insurance	Fire and other damage to property insurance	General liability insurance
		C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080
Gross — Direct Business	R0110	15,688,034	741,936	0	0	0	0	8,181,634	21,478,549
Gross — Proportional reinsurance accepted	R0120	0	0	0	0	0	0	0	0
Gross — Non-proportional reinsurance accepted	R0130								
Reinsurers' share	R0140	7,881,893	356,895	0	0	14,153	0	3,988,482	12,865,707
Net	R0200	7,806,141	385,040		0	-14,153		4,193,152	8,612,841
Premiums earned									
Gross — Direct Business	R0210	16,427,044	821,877	0	0	0	0	7,920,467	29,398,682
Gross — Proportional reinsurance accepted	R0220	0	0	0	0	0	0	0	99,230
Gross — Non-proportional reinsurance accepted	R0230								
Reinsurers' share	R0240	8,256,609	397,089	0	0	514,927	0	3,905,928	21,195,615
Net	R0300	8,170,435	424,788		0	-514,927		4,014,540	8,302,297
Claims incurred									
Gross — Direct Business	R0310	2,775,646	-492,806	0	-1,264,260	-453,869	0	4,278,772	69,420,653
Gross — Proportional reinsurance accepted	R0320	0	0	0	0	0	0	0	-1,308,109
Gross — Non-proportional reinsurance accepted	R0330								
Reinsurers' share	R0340	-1,117,456	-439,330	0	-1,251,060	-271,333	0	1,806,151	65,668,414
Net	R0400	3,893,102	-53,476		-13,200	-182,536		2,472,621	2,444,130
Expenses incurred	R0550	6,558,297	85,370	0	-9,661	-175,415	0	2,750,162	3,172,482
Administrative expenses									
Gross — Direct Business	R0610	151,110	7,856		0	-9,523		91,069	153,549
Gross — Proportional reinsurance accepted	R0620								
Gross — Non-proportional reinsurance accepted	R0630								
Reinsurers' share	R0640	2,942	153		0	-185		1,773	2,989
Net	R0700	148,168	7,703		0	-9,338		89,296	150,560
Investment management expenses									
Gross — Direct Business	R0710	74,501	3,873		0	-4,695		44,899	75,703
Gross — Proportional reinsurance accepted	R0720								
Gross — Non-proportional reinsurance accepted	R0730								
Reinsurers' share	R0740	40,511	2,106		0	-2,553		24,415	41,165
Net	R0800	33,989	1,767	0	0	-2,142	0	20,484	34,538
Claims management expenses									
Gross — Direct Business	R0810	746,585	144,643		33,141	-9,805		324,468	1,179,996
Gross — Proportional reinsurance accepted	R0820								
Gross — Non-proportional reinsurance accepted	R0830								
Reinsurers' share	R0840	353,312	120,398		0	0		130,359	868,652
Net	R0900	393,273	24,245	0	33,141	-9,805	0	194,109	311,344
Acquisition expenses									
Gross — Direct Business	R0910	9,133,277	616,191		0	-9,906		3,245,243	7,691,905
Gross — Proportional reinsurance accepted	R0920								
Gross — Non-proportional reinsurance accepted	R0930								
Reinsurers' share	R0940	5,234,490	672,890		42,802	12,879		2,054,974	7,133,578
Net	R1000	3,898,787	-56,699	0	-42,802	-22,785	0	1,190,269	558,327
Overhead expenses									
Gross — Direct Business	R1010	2,128,268	110,650	1	0	-134,130		1,282,635	2,162,616
Gross — Proportional reinsurance accepted	R1020		· · · · · · · · · · · · · · · · · · ·					,	
Gross — Non-proportional reinsurance accepted	R1030		· · · · · · · · · · · · · · · · · · ·	1		<u> </u>			· · · · · · · · · · · · · · · · · · ·
Reinsurers' share	R1040	44,190	2,297		0	-2,785		26,632	44,903
Net	R1100	2,084,079	108,353	0	0	-131,345	0	1,256,004	2,117,714
Balance - other technical expenses/income	R1210			1					
Total technical expenses	R1300		· · · · · · · · · · · · · · · · · · ·			· · · · · · · · · · · · · · · · · · ·			·



Annex 1
S.05.01 Premiums, claims and expenses by Line of Business – Non-Life (in €, as of December 31)

					Direct business and accepte	d proportional reinsurance				Total Non-Life obligation
					Direct business and accepte					
		Credit and suretyship insurance	Legal expenses insurance	Assistance	Miscellaneous financial loss	Non-proportional health reinsurance	Non-proportional casualty reinsurance	Non-proportional marine, aviation and transport reinsurance	Non-proportional property reinsurance	
		C0090	C0100	C0110	C0120	C0130	C0140	C0150	C0160	C0200
Premiums written							1	1		
Gross — Direct Business	R0110	40,662,598	3,445,731	0	193,496,433					283,694,914
Gross — Proportional reinsurance accepted	R0120	1,706,076	0	0	26,148,183	0	0	0	2 776 861	27,854,259
Gross — Non-proportional reinsurance accepted Reinsurers' share	R0130 R0140	20.599.914	1.640.183	0	129.532.173	0	0	0	2,776,861	2,776,861 178,285,819
Net	R0200	20,599,914	1,640,183	0	90.112.442	0	0	0	1,406,418	178,285,819
Premiums earned	KU200	21,/68,/60	1,805,547		90,112,442	0			1,570,444	130,040,216
Gross — Direct Business	R0210	48.499.402	3.935.264	0	192.633.635					299.636.371
Gross — Proportional reinsurance accepted	R0220	1.008.236	0	0	9.305.165					10.412.631
Gross — Non-proportional reinsurance accepted	R0230	1,000,230	Ü	-	3,303,103	0	0	0	2 584 396	2.584.396
Reinsurers' share	R0240	41.789.500	1.883.510	0	125.340.507	0	0	0	1,295,350	204.579.034
Net	R0300	7.718.137	2.051.754	-	76 598 293	0	0	0	1.289.047	108.054.364
Claims incurred						-	-	-		
Gross — Direct Business	R0310	6,217,668	126,377	0	100,569,852			I		181,178,034
Gross — Proportional reinsurance accepted	R0320	33,168	71	0	6,481,982					5,207,112
Gross — Non-proportional reinsurance accepted	R0330					0	0	0	509,512	509,512
Reinsurers' share	R0340	5,633,187	-506,859	0	58,408,356	0	0	0	249,253	128,179,323
Net	R0400	617,649	633,307	0	48,643,478	0	0	0	260,260	58,715,335
Expenses incurred	R0550	3,135,357	507,413	0	25,580,183	0	0	0	284,537	41,888,724
Administrative expenses										
Gross — Direct Business	R0610	149,765	37,947	0	1,416,669					1,998,442
Gross — Proportional reinsurance accepted	R0620									0
Gross — Non-proportional reinsurance accepted	R0630					0	0	0	0	0
Reinsurers' share	R0640	2,916	739	0	27,581	0	0	0	0	38,907
Net	R0700	146.849	37.208		1.389.088	0	0	0	0	1.959.535
Investment management expenses			1		1		T	1	1	
Gross — Direct Business	R0710	73,838	18,709	0	698,451					985,278
Gross — Proportional reinsurance accepted	R0720	-								0
Gross — Non-proportional reinsurance accepted	R0730					0	0	0	0	0
Reinsurers' share	R0740	40,151 33.687	10,173 8.535	0	379,798 318.653	0	0	0	0	535,766
Net	R0800	33,687	8,535	U	318,653	Ü	U		Ü	449,512
Claims management expenses Gross — Direct Business	R0810	788.213	39.677	0	4.354.829		1			7.601.747
Gross — Proportional reinsurance accepted	R0820	788,213	39,677	00	4,334,829					7,601,747
Gross — Non-proportional reinsurance accepted	R0830					0	0	0	0	0
Reinsurers' share	R0840	672 110	305		1.824.631	0	0	0	0	3 969 767
Net	R0900	116.103	39.372	0	2.530.198	0	0	0	0	3.631.980
Acquisition expenses				-		-		· ·	-	5/25-7/2-0-2
Gross — Direct Business	R0910	15,325,570	326,586		26,379,162					62.708.028
Gross — Proportional reinsurance accepted	R0920						Ì			0
Gross — Non-proportional reinsurance accepted	R0930				İ	0	0	0	284.537	284.537
Reinsurers' share	R0940	14,552,372	427,641	0	24,575,275	0	0	0	0	54,706,901
Net	R1000	773,198	-101,055	0	1,803,887	0	0	0	284,537	8,285,664
Overhead expenses			-	•						-
Gross — Direct Business	R1010	2,109,316	534,449	0	19,952,637	· · · · · · · · · · · · · · · · · · ·			`	28,146,443
Gross — Proportional reinsurance accepted	R1020			·		· · · · · · · · · · · · · · · · · · ·				0
Gross — Non-proportional reinsurance accepted	R1030					0	0	0	0	0
Reinsurers' share	R1040	43,796	11,097		414,280	0	0	0	0	584,410
Net	R1100	2,065,520	523,352	0	19,538,357	0	0	0	0	27,562,033
Balance - other technical expenses/income	R1210	<u> </u>			1					0
Total technical expenses	R1300				1		l			41,888,724



S.17.01 Non-Life Technical Provisions (in €, as of December 31)

					Direct busines	ss and accepted proport	ional reinsurance			
		Medical expense insurance	Income protection insurance	Workers' compensation insurance	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport insurance	Fire and other damage to property insurance	General liability insurance	Credit and suretyship insurance
		C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100
Technical provisions calculated as a whole	R0010									
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP calculated as a whole	R0050									
Technical provisions calculated as a sum of BE and RM Best Estimate Premium provisions										
Gross — Total	R0060	706,005	97,632					-132,664	35,743,675	22,477,768
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected	R0140	421,848	61,008					44.024	24 072 424	19,792,339
losses due to counterparty default Net Best Estimate of Premium Provisions	R0150	284,156	36.624					11,024 -143.688	31,073,431 4,670,245	2,685,429
Net best estimate of Fermani Tovisions	110130	204,130	30,024		l l			143,000	4,070,243	2,003,423
Claims provisions										
Gross — Total	R0160	15,525,867	10,464,117		4,054,432	452,776		6,837,215	332,500,950	64,109,663
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected	R0240									
losses due to counterparty default Net Best Estimate of Claims Provisions	R0250	13,639,865 1.886,002	10,005,801 458,316		3,863,930 190.502	424,073 28,703		3,857,869 2,979,346	313,748,498 18,752,452	53,555,100 10,554,562
Net best Estillate of Claims Provisions	N0230	1,000,002	430,310		150,302	28,703		2,373,340	10,732,432	10,334,302
Total Best estimate — gross	R0260	16,231,872	10,561,749		4,054,432	452,776		6,704,551	368,244,625	86,587,431
Total Best estimate — net	R0270	2,170,159	494,940		190,502	28,703		2,835,658	23,422,697	13,239,991
Risk margin	R0280	234,766	98,677		47,053	4,550		858,408	3,746,281	5,632,520
Amount of the transitional on Technical Provisions										
TP as a whole	R0290									
Technical provisions - total	R0300									
Risk margin	R0310									
Technical provisions - total Technical provisions - total	R0320	16,466,638	10,660,426		4,101,485	457,326		7,562,959	371,990,906	92,219,950
Recoverable from reinsurance contract/SPV and Finite Re after the adjustment for expected		10,400,038	10,000,420		4,101,465	457,320		7,302,939	371,990,900	92,219,950
losses due to counterparty default — total	R0330	14,061,713	10,066,809		3,863,930	424,073		3,868,893	344,821,928	73,347,440
Technical provisions minus recoverables from reinsurance/SPV and Finite Re- total	R0340	2,404,925	593,617		237,554	33,253		3,694,066	27,168,978	18,872,511
Line of Dusiness further compensation (Hamaganagus Bisk Crouns)										
Line of Business: further segmentation (Homogeneous Risk Groups) Premium provisions — Total number of homogeneous risk groups	R0350				ı			T T		
Claims provisions — Total number of homogeneous risk groups	R0360							+		

S.17.01 Non-Life Technical Provisions (in €, as of December 31)

			Direct business and accepted proportional reinsurance							
		Medical expense insurance	Income protection insurance	Workers' compensation insurance	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport insurance	Fire and other damage to property insurance	General liability insurance	Credit and suretyship insurance
		C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100
Cash-flows of the Best estimate of Premium Provisions (Gross)										
Cash out-flows					,	,				
Future benefits and claims	R0370	1,050,309	164,081					1,559,475	35,428,384	49,120,213
Future expenses and other cash-out flows	R0380	88,769	5,563					78,697	2,007,840	11,057,365
Cash in-flows					ı	ı				
Future premiums	R0390	433,073	72,012					1,770,836	1,692,549	37,699,810
Other cash-in flows (incl. Recoverable from salvages and subrogations)	R0400									
Cash-flows of the Best estimate of Claims Provisions (Gross) Cash out-flows										
Future benefits and claims	R0410	14,856,678	9,941,508		3,868,648	426,655		6,458,301	317,922,965	49,524,745
Future expenses and other cash-out flows	R0420	2,586,114	535,914		185,784	26,121		659,753	14,820,927	12,476,460
Cash in-flows										
Future premiums	R0430	1,916,925	13,305					280,838	242,942	-2,108,458
Other cash-in flows (incl. Recoverable from salvages and subrogations)	R0440									
,										
					T	T				
Percentage of gross Best Estimate calculated using approximations	R0450									
Best estimate subject to transitional of the interest rate	R0460									
Technical provisions without transitional on interest rate	R0470									
					L	l.				
Best estimate subject to volatility adjustment	R0480									
Technical provisions without volatility adjustment and without others transitional measures	R0490									
Expected profits included in future premiums (EPIFP)	R0500	801,099	16,039					361,172	592,558	13,280,799

S.17.01 Non-Life Technical Provisions (in €, as of December 31)

		Direct business	and accepted proportional	reinsurance		Accepted non-proportio	nal reinsurance		Total Non-Life obligation
		Legal expenses insurance	Assistance	Miscellaneous financial loss	Non-proportional health reinsurance	Non-proportional casualty reinsurance	Non-proportional marine, aviation and transport reinsurance	Non-proportional property reinsurance	
		C0110	C0120	C0130	C0140	C0150	C0160	C0170	C0180
Technical provisions calculated as a whole	R0010								
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP calculated as a whole	R0050								
Technical provisions calculated as a sum of BE and RM									
Best Estimate									
Premium provisions						1		1	
Gross — Total	R0060	253,177	22	28,674,111				-3,632,969	84,186,756
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0140	142,563	21	16,491,602				-1,097,346	66,896,490
Net Best Estimate of Premium Provisions	R0150	110,614		12,182,509				-2,535,623	17,290,267
Claims provisions	R0160			1		I		I I	
Gross — Total	KU16U	10,618,596	381,008	79,420,167				1,351,717	525,716,508
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0240	9,937,591	378,847	49,698,107				552,010	459,661,692
Net Best Estimate of Claims Provisions	R0250	681,005	2,161	29,722,060				799,707	66,054,816
	R0260								
Total Best estimate — gross	R0270	10,871,773	381,030	108,094,278				-2,281,252	609,903,264
Total Best estimate — net	110270	791,618	2,161	41,904,569				-1,735,916	83,345,082
Risk margin	R0280	127,367	2,909	4,679,995				608,404	16,040,930
Amount of the transitional on Technical Provisions	R0290								
TP as a whole	R0300								
Best Estimate	R0310								
Risk margin	110310			L					
Technical provisions - total									
Technical provisions - total	R0320	10,999,140	383,939	112,774,273				-1,672,848	625,944,193
Recoverable from reinsurance contract/SPV and Finite Re after the adjustment for expected losses	R0330								
due to counterparty default — total		10,080,154	378,869	66,189,709				-545,336	526,558,182
Technical provisions minus recoverables from reinsurance/SPV and Finite Re- total	R0340	918,985	5,070	46,584,564				-1,127,512	99,386,012
Line of Business: further segmentation (Homogeneous Risk Groups)									
Premium provisions — Total number of homogeneous risk groups	R0350								
Claims provisions — Total number of homogeneous risk groups	R0360								
				I.		1		1	



S.17.01 Non-Life Technical Provisions (in €, as of December 31)

		insurance	Assistance	loss	reinsurance	casualty reinsurance	aviation and transport reinsurance	property reinsurance	
		C0110	C0120	C0130	C0140	C0150	C0160	C0170	C0180
Cash-flows of the Best estimate of Premium Provisions (Gross)									
Cash out-flows						1		1	
Future benefits and claims	R0370	535,856	22	67,605,727				2,623,090	158,087,157
Future expenses and other cash-out flows	R0380	10,810		6,182,793				459,075	19,890,914
Cash in-flows									
Future premiums	R0390	293,490		45,114,409				6,715,134	93,791,315
Other cash-in flows (incl. Recoverable from salvages and subrogations)	R0400								
Cash-flows of the Best estimate of Claims Provisions (Gross)									
Cash out-flows						1			
Future benefits and claims	R0410	10,966,520	43,867	71,407,265				1,054,747	486,471,900
Future expenses and other cash-out flows	R0420	562,998	337,141	36,386,489				307,575	68,885,275
Cash in-flows						,		,	
Future premiums	R0430	910,922		28,373,587				10,606	29,640,667
Other cash-in flows (incl. Recoverable from salvages and subrogations)	R0440								
						1		<u> </u>	
Percentage of gross Best Estimate calculated using approximations	R0450								
Best estimate subject to transitional of the interest rate	R0460								
Technical provisions without transitional on interest rate	R0470								
recnnical provisions without transitional on interest rate									
Best estimate subject to volatility adjustment	R0480								
Technical provisions without volatility adjustment and without others transitional measures	R0490								
**						•		·	
Expected profits included in future premiums (EPIFP)	R0500	193,699		15,266,405				3,857,514	34,369,285

Total Non-Life obligation

Non-proportional marine,

Non-proportional

S.19.01.21 Non-Life Insurance Claims Information (in €, as of December 31)

Gross Claims Paid (non-

(absolute amount € '000)

	·		•			Developi	ment year					
	Year	0	1	2	3	4	5	6	7	8	9	10 & +
		C010	C020	C030	C040	C050	C060	C070	C080	C090	C0100	C0110
Prior	R0100											22,929
N_9	R0160	50,978	88,235	39,298	29,114	24,165	10,648	25,097	22,966	22,146	18,447	
N_8	R0170	64,293	92,443	41,517	34,073	17,348	22,230	21,157	47,807	30,883		
N_7	R0180	98,061	101,473	51,549	34,972	29,591	30,488	42,827	34,275			
N_6	R0190	69,485	118,421	54,619	40,086	24,283	30,279	18,874				
N_5	R0200	62,282	94,962	44,658	32,512	18,565	9,621					
N_4	R0210	55,015	82,702	34,763	14,349	11,296						
N_3	R0220	51,041	57,525	30,016	17,123							
N_2	R0230	44,950	49,552	13,949								
N_1	R0240	44,741	50,743		•							
N	R0250	46,035										

		In Current
		Year
		C0170
Prior	R0100	22,929
N_9	R0160	18,447
N_8	R0170	30,883
N_7	R0180	34,275
N 6	R0190	18,874
N_5	R0200	9,621
N_4	R0210	11,296
N_3	R0220	17,123
N_2	R0230	13,949
N_1	R0240	50,743
V	R0250	46,035
Total	R0260	274,177
		•

Sum of years (cumulative)
C0180
22,929
331,094
371,749
423,237
356,048
262,601
198,125
155,705
108,451
95,484
46,035
2,371,458
·

Gross undiscounted Best Estimate Claims Provision

(absolute amount € '000)

Deve	lopment	yea
------	---------	-----

	Year											10 & +
		C0200	C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0290	C0300
Prior	R0100											56,188
N_9	R0160	66,589	95,866	88,736	79,635	64,633	69,439	62,415	65,973	43,692	31,419	
N_8	R0170	81,128	106,934	113,773	101,100	99,848	96,994	132,122	118,158	85,174		
N_7	R0180	104,470	128,440	128,871	130,650	114,634	103,401	112,837	96,017		•	
N_6	R0190	87,234	116,578	117,616	117,740	107,618	102,300	100,488				
N_5	R0200	60,699	69,914	63,855	52,956	24,422	18,460					
N_4	R0210	72,741	72,831	67,157	37,605	26,647						
N_3	R0220	80,092	98,147	59,694	44,764							
N_2	R0230	52,018	43,468	30,494								
N_1	R0240	31,930	34,365		•							
N	R0250	38,993		•								

Year end (discounte d data)

		C0170
rior	R0100	51,279
_9	R0160	29,313
8	R0170	79,665
_7	R0180	88,985
_6	R0190	93,036
_5	R0200	17,374
_4	R0210	25,278
_3	R0220	41,977
_2	R0230	28,786
1	R0240	32,599
	R0250	37,423
Total	R0260	525,717

S.23.01.01 Own Funds (*in* €, *as of December 31*)

		C0010	C0020	C0030	C0040	C0050
Ordinary share capital (gross of own shares)	R0010	1,946,008	1,946,008	0	0	0
Share premium account related to ordinary share capital	R0030	13,270,299	13,270,299	0	0	0
Initial funds, members' contributions or the equivalent basic own — fund item for mutual and	R0040	0	0	0	O	0
Subordinated mutual member accounts	R0050	0	0	0	0	0
Surplus funds	R0070	0	0	0	0	0
Preference shares	R0090	0	0	0	0	0
Share premium account related to preference shares	R0110	0	0	0	0	0
Reconciliation reserve	R0130	140,263,980	140,263,980	0	0	0
Subordinated liabilities	R0140	0	0	0	0	0
An amount equal to the value of net deferred tax assets	R0160	3,514,741	0	0	0	3,514,741
Other items approved by supervisory authority as basic own funds not specified above	R0180	56,856,048	56,856,048	0	0	0
Own funds from the financial statements that should not be represented by the reconciliation						
,	Ī	Total				
	Ī	C0010				
Own funds from the financial statements that should not be represented by the reconciliation	R0220	0				
	-					
	г				T	
Deductions	-	Total	Tier 1 — unrestricted	Tier 1 — restricted	Tier 2	Tier 3
		C0010	C0020	C0030	C0040	C0050
Deductions for participations in financial and credit institutions	R0230	0	0	0	1 0	0
	Γ	Total	Tier 1 — unrestricted	Tier 1 — restricted	Tier 2	Tier 3
	Ī	C0010	C0020	C0030	C0040	C0050
Total basic own funds after deductions	R0290	215,851,076	212,336,335	0	0.00	3,514,741
				-		
	F					
Ancillary own funds	L	Total			Tier 2	Tier 3
	Ļ	C0010			C0040	C0050
Unpaid and uncalled ordinary share capital callable on demand	R0300	0			0	0
Unpaid and uncalled initial funds, members' contributions or the equivalent basic own fund item		0			0	0
Unpaid and uncalled preference shares callable on demand	R0320	0			0	0
A legally binding commitment to subscribe and pay for subordinated liabilities on demand	R0330	0			0	0
Letters of credit and guarantees under Article 96(2) of the Directive 2009/138/EC	R0340	0			0	0
Letters of credit and guarantees other than under Article 96(2) of the Directive 2009/138/EC	R0350	0			0	0
Supplementary members calls under first subparagraph of Article 96(3) of the Directive	R0360	0			0	0
Supplementary members calls — other than under first subparagraph of Article 96(3) of the	R0370	0			0	0
Other ancillary own funds	R0390	0			0	0
Total ancillary own funds	R0400	0			0	0

Total

Tier 1 — unrestricted

Tier 1 — restricted

Tier 2

Tier 3

Annex 1 S.23.01.01 Own Funds (in €, as of December 31)

Total available own funds to meet the SCR
Total available own funds to meet the MCR

Total eligible own	funds	to	meet	the	SCR
Total eligible own	funds	to	meet	the	MCR

SCR MCR Ratio of Eligible own funds to SCR Ratio of Eligible own funds to MCR

Reconciliation reserve

Excess of Assets over Liabilities

Own shares (held directly and indirectly)

Foreseeable dividends, distributions and charges

Other basic own fund items

Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds

Reconciliation reserve

Expected profits included in future premiums (EPIFP) — Life business Expected profits included in future premiums (EPIFP) — Non- life business Total Expected profits included in future premiums (EPIFP)

	Total	Tier 1 — unrestricted	Tier 1 — restricted	Tier 2	Tier 3
	C0010	C0020	C0030	C0040	C0050
R0500	215,851,076	212,336,335	0	0	3,514,741
R0510	212,336,335	212,336,335	0	0	0

	Total	Tier 1 — unrestricted	Tier 1 — restricted	Tier 2	Tier 3
	C0010	C0020	C0030	C0040	C0050
R0540	215,851,076	212,336,335	0	0	3,514,741
R0550	212,336,335	212,336,335	0	0	0

	C0010
R0580	129,180,525
R0600	32,295,131
R0620	167.09%
R0640	657.49%

C0060	
215,851,076	R0700
O	R0710
O	R0720
75,587,097	R0730
0	R0740
140,263,980	R0760

	C0060
R0770	0
R0780	34,369,285
R0790	34,369,285

Annex 1 S.25.01.21 Solvency Capital Requirement for undertakings on Standard Formula (in €, as of December 31)

					Only relevant for p	oublic disclosure
		Net solvency capital requirement	Gross solvency capital requirement	Allocation from adjustments due to RFF and Matching adjustments portfolios	Simplifications	USP
		C0030	C0040	C0050	C0120	C0090
Market risk	R0010	23,457,125	23,457,125	0	0	0
Counterparty default risk	R0020	23,725,181	23,725,181	0	0	0
Life underwriting risk	R0030	0	0	0	0	0
Health underwriting risk	R0040	1,704,772	1,704,772	0	0	0
Non-life underwriting risk	R0050	87,984,383	87,984,383	0	0	0
Diversification	R0060	-25,988,034	-25,988,034	0	0	0
Intangible asset risk	R0070	0	0	0	0	0
Basic Solvency Capital Requirement	R0100	110,883,427	110,883,427	0	0	0
Calculation of Solvency Capital Requirement		C0100				
Adjustment due to RFF/MAP nSCR aggregation	R0120	0				
Operational risk	R0130	18,297,098				
Loss-absorbing capacity of technical provisions	R0140	0				
Loss-absorbing capacity of deferred taxes	R0150	0				
Capital requirement for business operated in accordance with Art. 4 of Directive	R0160	0				

Calculation of Solvency Capital Requirement		C0100
Adjustment due to RFF/MAP nSCR aggregation	R0120	0
Operational risk	R0130	18,297,098
Loss-absorbing capacity of technical provisions	R0140	0
Loss-absorbing capacity of deferred taxes	R0150	0
Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC	R0160	0
Solvency Capital Requirement excluding capital add-on	R0200	129,180,525
Capital add-ons already set	R0210	0
Solvency capital requirement for undertakings under consolidated method	R0220	129,180,525
Other information on SCR		
Capital requirement for duration-based equity risk sub-module	R0400	0
Total amount of Notional Solvency Capital Requirements for remaining part	R0410	0
Total amount of Notional Solvency Capital Requirements for ring fenced funds	R0420	0
Total amount of Notional Solvency Capital Requirements for matching adjustment portfolios	R0430	0
Diversification effects due to RFF nSCR aggregation for article 304	R0440	0
Method used to calculate the adjustment due to RFF/MAP nSCR aggregation	R0450	4: No adjustment
Net future discretionary benefits	R0460	0

S.28.01.21 Minimum Capital Requirement — Only life or only non-life insurance or reinsurance activity (in €, as of December 31)

		C0010	
Linear formula component for non-life insurance and reinsurance obligations	R0010	28,624,198	
		Net (of reinsurance/SPV) best estimate	Net (of reinsurance) written premiums in the last 12
		and TP calculated as a whole	months
		C0020	C0030
Medical expense insurance and proportional reinsurance	R0020	2,170,159	7,806,141
Income protection insurance and proportional reinsurance	R0030	494,940	385,040
Workers' compensation insurance and proportional reinsurance	R0040	0	0
Motor vehicle liability insurance and proportional reinsurance	R0050	190,502 28,703	0
Other motor insurance and proportional reinsurance	R0060 R0070	28,703	<u> </u>
Marine, aviation and transport insurance and proportional reinsurance	R0070	2,835,658	5,184,055
Fire and other damage to property insurance and proportional reinsurance General liability insurance and proportional reinsurance	R0090	23,422,697	8,612,827
Credit and suretyship insurance and proportional reinsurance	R0100	13,239,991	22,148,314
Legal expenses insurance and proportional reinsurance	R0110	791,618	1,805,547
Assistance and proportional reinsurance	R0120	2,161	1,003,547
Miscellaneous financial loss insurance and proportional reinsurance	R0130	41,904,569	90,112,442
Non-proportional health reinsurance	R0140	0	0
Non-proportional casualty reinsurance	R0150	0	0
Non-proportional marine, aviation and transport reinsurance	R0160	0	0
Non-proportional property reinsurance	R0170	0	0
		C0040	
Linear formula component for life insurance and reinsurance obligations	R0200	0	
Linear formatic component for the institution and remodulate obligations	110200		
		Net (of reinsurance/SPV) best estimate	Net (of reinsurance/SPV) total capital at risk
		and TP calculated as a whole	
		C0050	C0060
Obligations with profit participation — guaranteed benefits	R0210	0	0
Obligations with profit participation — future discretionary benefits	R0220 R0230	0	0
Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations	R0240	0	0
Total capital at risk for all life (re)insurance obligations	R0240	0	0
Total capital at 11sk for all life (re)lifsulance obligations	110230		5
Overall MCR calculation		C0070	
Linear MCR	R0300	28,624,198	
SCR	R0310	129,180,525	
MCR cap	R0320	58,131,236	
MCR floor	R0330	32,295,131	
Combined MCR	R0340	32,295,131	
Absolute floor of the MCR	R0350	4,000,000	
Minimum Capital Requirement	R0400	32,295,131	